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Abstract
The transcription factor GATA2 is highly expressed in hematopoietic stem cells (HSCs) and is
downregulated during differentiation. Overexpression of GATA2 is frequently observed in acute myeloid
leukemia. In previous studies, enforced expression of GATA2 using a MSCV GATA2 retroviral vector
blocked differentiation of HSC and progenitors without inducing leukemia. We hypothesized that a lower
dose of GATA2 can relieve the HSC block and eventually transform myeloid progenitors into leukemia
stem cells. To test this hypothesis we generated a MSCV GATA2-ERT vector in which nuclear
concentration of GATA2 can be regulated by Tamoxifen (TAM). The GATA2-ERT protein was confirmed to
leak into nucleus of transduced BM cells even in the absence of TAM. This low nuclear GATA2-ERT led to
enhanced self-renewal of myeloid progenitors in vitro and was able to immortalize primary bone marrow
(BM) cells into IL-3 dependent myeloid cell lines. Continuous GATA2-ERT expression was also required for
the proliferation of these immortalized lines. Nmyc and HoxA9 mRNA were significantly higher in
GATA2-ERT immortalized lines compared to control immortalized lines. Repression of either Nmyc or
Hoxa9 in GATA2-ERT immortalized cells impaired their proliferation suggesting that they are potential
GATA2 targets mediating this effect.
Myeloid expansion and a block in T cell and B cell lineage differentiation was observed in transplant
recipients of GATA2-ERT expressing BM cells without TAM. The myeloid expansion occurs after the
Granulocyte Monocyte Progenitor (GMP) and the lymphoid block occurs after the Common Lymphoid
Progenitor (CLP) in transgenic mice. Finally using the C352P mutant we showed that myeloid expansion
and B lymphoid block require DNA binding activity of GATA2-ERT and were not due to the dominant
negative effect of the cytosolic form of this protein.
We were the first to demonstrate that GATA2 overexpression confers increased selfrenewal of myeloid
progenitors which correlates with increased GATA2 mRNA levels frequently observed in human AML
patients. We believe that the lower dose of GATA2 is critical to this phenotype. Interestingly no myeloid
leukemias were observed in both the transplant and transgenic animals.
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ABSTRACT
The transcription factor GATA2 is highly expressed in hematopoietic stem cells
(HSCs) and is downregulated during differentiation. Overexpression of GATA2 is
frequently observed in acute myeloid leukemia. In previous studies, enforced expression
of GATA2 using a MSCV GATA2 retroviral vector blocked differentiation of HSC and
progenitors without inducing leukemia. We hypothesized that a lower dose of GATA2
can relieve the HSC block and eventually transform myeloid progenitors into leukemia
stem cells. To test this hypothesis we generated a MSCV GATA2-ERT vector in which
nuclear concentration of GATA2 can be regulated by Tamoxifen (TAM). The
GATA2-ERT protein was confirmed to leak into nucleus of transduced BM cells even in
the absence of TAM. This low nuclear GATA2-ERT led to enhanced self-renewal of
myeloid progenitors in vitro and was able to immortalize primary bone marrow (BM)
cells into IL-3 dependent myeloid cell lines. Continuous GATA2-ERT expression was
also required for the proliferation of these immortalized lines. Nmyc and HoxA9 mRNA
were significantly higher in GATA2-ERT immortalized lines compared to control
immortalized lines. Repression of either Nmyc or Hoxa9 in GATA2-ERT immortalized
cells impaired their proliferation suggesting that they are potential GATA2 targets
mediating this effect.
Myeloid expansion and a block in T cell and B cell lineage differentiation was
observed in transplant recipients of GATA2-ERT expressing BM cells without TAM.
The myeloid expansion occurs after the Granulocyte Monocyte Progenitor (GMP) and
the lymphoid block occurs after the Common Lymphoid Progenitor (CLP) in transgenic
mice. Finally using the C352P mutant we showed that myeloid expansion and B
lymphoid block require DNA binding activity of GATA2-ERT and were not due to the
dominant negative effect of the cytosolic form of this protein.
We were the first to demonstrate that GATA2 overexpression confers increased
self-renewal of myeloid progenitors which correlates with increased GATA2 mRNA
levels frequently observed in human AML patients. We believe that the lower dose of
GATA2 is critical to this phenotype. Interestingly no myeloid leukemias were observed
in both the transplant and transgenic animals.
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CHAPTER 1.

INTRODUCTION

Hematopoiesis in the Adult Bone Marrow
Bone marrow (BM) is the primary site of blood production (hematopoiesis) in
both adult mice and humans. The understanding that the BM is the site of hematopoiesis
came from studies on radiation injury. In 1945 Hiroshima and Nagasaki atomic bomb
victims were found to have died of hematopoietic failure.1 Later it was shown that a
similar radiation syndrome in mice could be prevented by BM transplantation.2-4 In 1961,
Till and McCulloch showed that BM cells transplanted into lethally irradiated mice
formed spleen colonies (CFU-S) which contained a clonal population of myeloerythroid
cells (granulocytes, macrophages, red cells and megakaryocytes) and cells of lymphoid
potential.5-7 Some cells from these CFU-Ss can form additional CFU-S upon secondary
transplantation. Till and McCulloch were the first to propose the existence of a
hematopoietic stem cell (HSC) which can self-renew and differentiate into all blood cell
types. This led to the search for the Hematopoietic Stem cell in the BM. Between 1988
and 1992, the Weissman group successfully isolated the murine HSC by enrichment of
BM cells expressing stem cell markers (Sca-1, c-kit, Thy1.1) and depletion of cells
expressing the mature “lineage markers” (Gr-1, Mac-1, B220, CD4, CD8,Ter-119 and
NK1.1).8,9 Subsequently it was also shown that all the HSCs of the mouse BM were
located in this c-kit+, Thy1.1low, Lin-, Sca1+ (KTLS) compartment of the BM.10
Two models of lineage commitment from the HSC have been proposed so far
(Figure 1-1). The KTLS cells are a heterogeneous population of multipotent cells with
different self-renewal capacities.11 Within the KTLS cells the Long Term HSCs (LTHSCs) are the true HSCs which have the self-renewal capacity for the life-time of the
organism. The LT-HSCs gives rise to the Short Term HSCs (ST-HSCs) with the selfrenewal capacity of less than 8 weeks and their progeny the Multipotent Progenitors
(MPPs) with no self-renewal capacity.12 In the first model proposed by the Weissman
group, the ST-HSCs or MPPs gives rise to either a Common Lymphoid Progenitor (CLP)
or a Common Myeloid Progenitor (CMP) which in turn gives rise to either a
Granulocyte-Macrophage Progenitor (GMP) or a Megakarocyte-Erythroid Progenitor
(MEP).13 In the alternate model proposed by the Jacobsen group, the MEP is derived
directly from the ST-HSCs/MPPs and a Lymphoid-Primed Multipotential Progenitor
(LMPP) gives rise to the CLP and the GMP.14 The CLP, GMP, and MEP in turn
differentiate into respective differentiated cells (CLP: T-cells, B-cells, NK cells; GMP:
neutrophils, basophils, eosinophil’s, macrophages, mast cells; MEP: Red blood cells,
platelets) through intermediate progenitor stages. The T-cell progenitors are unique that
they also retain the ability to differentiate into myeloid cells at early stages.15,16 All the
various stem cells, progenitor cells and mature cells described above can now be isolated
based on their surface marker expression (Table 1-1). Recently Orkin's group did a
computational mapping based on multiplex single cell quantitative PCR analysis (280
cell surface markers) and generated a hierarchy similar to the Jacobsen model.17
Furthermore, they also demonstrated that a subset of MPPs generates preferentially
megakaryocytes and RBCs showing that the Jacobsen model is more relevant.17
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Figure 1-1. Proposed models for the hematopoietic hierarchy.
In the model proposed by the Weissman group (solid arrows), multipotential progenitors
(MPPs or short-term HSCs [ST-HSCs]) give rise to either a common lymphocyte
progenitor (CLP) or a common myeloid progenitor (CMP), which, in turn, gives rise to
either a granulocyte-macrophage progenitor (GMP, equivalent to CFU-GM) or a
megakaryocyte-erythroid progenitor (MEP). The alternate model suggested by the
Jacobson group (dotted arrows) involves the generation of MEPs directly from the
MPPs/ST-HSCs, whereas a lymphoid-primed multipotential progenitor (LMPP) has the
potential to generate both CLPs and GMPs. LT-HSC, Long-term hematopoietic stem cell;
NK cell, natural killer cell.
Reprinted with permission: Dzierzak E, Philipsen S. Erythropoiesis: development and
differentiation. Cold Spring Harb Perspect Med. 2013;3(4).18
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Table 1-1.

Cell surface phenotypes of different hematopoietic populations.
Population Name
LT-HSC
LT-HSC (SLAM)
LT-HSC (SP)
ST-HSC / MPP
LMPP
CLP
CMP
GMP
MEP
B-cells
T-cells
NK cells
RBC
Platelets
Granulocytes
Macrophages

Surface Markers
Lin- c-Kit+ Sca1+ Flt3- CD34Lin- c-Kit+ Sca1+ CD150+ CD48Lin- c-Kit+ Sca1+ Hoechst side population
Lin- c-Kit+ Sca1+ Flt3- CD34+
Lin- c-Kit+ Sca1+ Flt3+ CD34+
Lin- c-Kitlow Sca1low Flt3high IL7Rα+
Lin- c-Kit+ Sca1- CD34+ FcγRlow
Lin- c-Kit+ Sca1- CD34+ FcγR+
Lin- c-Kit+ Sca1- CD34- FcγRB220
CD3, CD4 and CD8
NK1.1
Ter119
CD41
Gr-1
Mac-1

HSC: Hematopoietic Stem Cell, LT-HSC: Long Term HSC, ST-HSC: Short Term HSC,
MPP: Multipotent Progenitors, LMPP: Lymphoid primed multipotent progenitor, CLP:
Common Lymphoid progenitor, CMP: Common myeloid progenitor, GMP: Granulocytemacrophage progenitor, MEP: Megakaryocyte-Erythroid progenitor, Lin: Lineage
markers.
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Origins of the Hematopoietic System
Even though the BM is the primary site of hematopoiesis in the adult, the HSCs
are not normally generated de-novo in the BM but are colonized during embryonic
development from other sites. During embryogenesis, hematopoiesis occurs sequentially
at different sites and hematopoietic cells later colonize secondary territories to finally end
up in the BM (Figure 1-2).19 The first wave of hematopoiesis is detectable at embryonic
day 7.5 (E 7.5) in the yolk sac blood islands. This is called the primitive hematopoiesis
and it generates red blood cells that express embryonic globins. The primitive
hematopoiesis is transient and is replaced by definitive hematopoiesis which is
characterized by expression of adult type globins. The first site of definitive
hematopoiesis is located in the Aorto-Gonado-Mesonephros (AGM) region at E10.5. In
this region, “hemogenic endothelial cells” on the ventral side of the dorsal aorta bud off
hematopoietic stem cells. The hematopoietic cells in the AGM region are capable of
reconstituting hematopoiesis in lethally irradiated mice.20 At a similar time hematopoietic
clusters are also found in the umbilical arteries, allantois and the placenta.21-23 The
relative contribution of these sites to the final pool of adult HSCs is still unknown. The
definitive hematopoietic cells then migrate into the fetal liver, thymus, spleen and finally
the BM (Figure 1-2). The properties of HSCs in these niches are different, for example
the fetal liver HSCs are cycling compared to the BM HSCs which are mostly quiescent.19
Transcription Factors in Hematopoiesis
The importance of Transcription Factors (TFs) in hematopoiesis can be
appreciated by the fact that their dysregulated expression and mutations are frequently
found in leukemia.24-26 Hematopoietic transcription factors can be arbitrarily classified
into “HSC specific” TFs and “lineage specific” TFs. The HSC specific TFs like Scl/Tal1
and Runx-1 are required for generation of the HSC. Scl/Tal1 knockout mice is embryonic
lethal with no blood formation in the yolk sac and embryo indicating its importance in
both primitive and definitive hematopoiesis.27-29 Runx-1 knockout mice had normal
primitive hematopoiesis but fail to form hematopoietic clusters in the AGM region, the
first site of definitive hematopoiesis.30-32 On the other hand, Lineage specific TFs like
CEBPα and GATA1are required for the generation of specific lineages. Mature
neutrophils and eosinophils are absent in the blood and fetal liver of CEBPα-/- mice while
other lineages are not affected.33 Similarly GATA1-/- ES cells do not contribute to mature
red blood cells in chimeras but do generate other non-erythroid lineages.34
However this classification is not strict and frequently HSC specific TFs also have
other functions in specific lineages and the lineage specific TFs have also have functions
in the HSCs. Conditional inactivation of SCL/Tal1 in the adult bone marrow did not
affect HSC self-renewal or maintenance but specifically blocked the differentiation of
erythroid and megakaryocyte lineages.35 Similarly conditional inactivation of Runx1 in
the adult bone marrow specifically blocked differentiation of megakaryocytes and
lymphocytes without affecting HSCs.36 Conditional inactivation of the lineage specific
TF, CEBPα in the fetal liver also expanded the HSCs as shown by increased competitive
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Figure 1-2. Timeline of hematopoietic events in the mouse conceptus.
Arrows above indicate the onset of specific hematopoietic cell generation and/or
appearance; arrows below indicate the earliest time of colonization of the secondary
hematopoietic territories. AGM, Aorto Gonado Mesonephros region.
Reprinted with permission: Dzierzak E, Speck NA. Of lineage and legacy: the
development of mammalian hematopoietic stem cells. Nat Immunol. 2008;9(2):129136.37
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repopulation.38 This shows that lineage specific TFs may also have HSC functions.
Redeployment of the same TF during different stages of development and differentiation
is commonly found in hematopoiesis.
Lineage specific TFs promote their own lineage differentiation and at the same
time antagonize TFs that favor other lineage choices. GATA1 and PU.1 are essential for
erythroid and myeloid differentiation respectively. N-terminus region of PU.1 was shown
to physically interact with the C-terminus zinc finger region of GATA1 and prevent its
function by affecting the DNA binding ability.39,40 The C-terminus zinc finger of GATA1
can also block PU.1 mediated transactivation of myeloid specific genes by interacting
with its ETS domain.41. Forced expression of GATA1 in myeloid cells reprograms them
to undergo erythroid differentiation.42 Forced expression of PU.1 represses erythropoiesis
and promotes myeloid differentiation in erythroid cell lines.43 Morpholino based
knockdown of PU.1 and GATA1 in zebrafish shifts hematopoietic progenitors into
erythroid and myeloid fates respectively.44,45 TFs can also antagonize each other at the
level of transcription. For example during erythroid differentiation GATA1 and GATA2
antagonize each other at the transcriptional level. This phenomenon is called the “GATA
switch “and will be discussed in detail later.
TFs can also mediate lineage choices in a dose dependent manner. This has been
demonstrated for PU.1 and GATA1. When PU.1-/- fetal liver cells were transduced with a
PU.1iresGFP vector and cultured on OP9 cells they differentiate into macrophages and B
cells. Expression of high GFP in the macrophages and low GFP in the B cells showed
that PU.1 can differentiate fetal liver progenitors into different lineages based on
dosage.46 Expression of GATA1 in myb-ets transformed avian myeloblasts showed a
clear co-relation of GATA1 dosage and lineage choice.47 Eosinophils formed at low
doses of GATA1 and erythroid, megakaryocyte development is seen at high doses.
TFs can group together with other TFs and non-DNA binding proteins to form
multiprotein complexes. In erythroid cells a complex containing Scl/Tal1, E47, LMO2,
Ldb1 and GATA1 has been reported.48 This complex binds to DNA sequences with
composite elements containing both GATA motif (WGATAR) and E-box motif
(CAANNTG).48 GATA1 also forms an alternate protein complex with its co-factor
Friend of GATA (FOG). Using GATA1 mutants which cannot bind to FOG1 but have
normal DNA binding activity, it has been shown that this GATA-FOG complex is
essential for erythroid and megakaryocyte development.49 GATA1-FOG1 complex is
further associated with the NuRD chromatin remodeling complex in both erythroid and
megakaryocyte lineages through N-terminus NuRD interaction domain of FOG1.50 This
association can mediate transcriptional repression and also facilitate accessibility of the
complex to its target regions.
GATA Family of Transcription Factors
The GATA binding proteins are a group of structurally related zinc finger
transcription factors which bind to the consensus DNA sequence WGATAR (W=A/T,
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R=A/G). In mammals the GATA family contains 6 members (GATA1- GATA6).
GATA1, GATA2 and GATA3 are primarily expressed in the hematopoietic system.
GATA1 and GATA3 are lineage specific transcription factors. GATA1 is expressed in
the erythroid, megakaryocyte and eosinophil lineages whereas GATA3 is expressed in
the T cell lineage.51 GATA2 is broadly expressed in the HSCs, progenitors and mast
cells.52,53 These hematopoietic GATA members are also expressed in other tissues in the
body. GATA1 is expressed in the Sertoli cells in testes.54 GATA2 is expressed in
endothelial cells, fetal liver, fetal heart, placenta, brain and pituitary glands.55-59 GATA3
is expressed in kidney, central nervous system, placenta, skin and mammary glands.60-62
The other GATA family members, GATA4, GATA5, and GATA6 are expressed in
tissues of mesodermal and endodermal origins such as heart, liver, lung, gut and
gonads.63
The functions of the hematopoietic GATA factors have been studied using
knockout mice. GATA1-/- embryos die between embryonic day 10.5 and 11.5 due to a
block in the differentiation of embryonic erythroid cells. GATA1-/- ES cells in chimeras
did not contribute to the erythroid lineage but had normal contribution to other lineages.34
Subsequently it was shown that targeted deletion of two control elements in the GATA1
locus lead to loss of eosinophil lineage and defects in platelet development.64,65 These
experiments showed that GATA1 is required for lineage specification of erythroid,
megakaryocyte and eosinophil lineages. GATA2-/- embryos die between embryonic day
10 and 11 due to severe anemia. GATA2-/- ES cells did not contribute to any
hematopoietic cells showing a defect in HSC formation.66 GATA3-/- embryos die due to
internal bleeding, aberrations in fetal hematopoiesis, abnormalities in spinal cord and
brain.67 GATA3-/- ES cells in RAG2-/- chimeras did not contribute to the T-cell lineage
but had normal contribution to other lineages.68
In some instances the functions of GATA factors were shown to be partially
interchangeable. When GATA3 is knocked into the endogenous GATA1 locus, the
mutant mice showed a partial rescue of the GATA1 null phenotype characterized by
increased survival of erythroid precursors and improved hemoglobin production.69
Transgenic expression of GATA2 and GATA3 could rescue embryonic lethality of
GATA1 knockdown embryos.70 However the adult mice rescued with the transgenes
developed anemia.70 In T-cells GATA3 target genes can be activated and repressed by
expression of GATA1, 2 and 4.71
The GATA factors contain two highly conserved Cys4 zinc fingers. The Cterminal zinc finger is necessary and sufficient for GATA to bind to cognate sequence
WGATAR.72,73 The N-terminal zinc finger can also bind to DNA sequence containing
GATC74,75 and also mediates binding to co-regulator FOG1. Recently Chip-Seq
experiments with GATA1,GATA2 and GATA3 factors has shown that GATA factors
mostly bind to single GATA site ((A/T) GATAA) or a palindromic site
(catctGATAAG).76-78 Crystal structure analysis of DNA binding domain of GATA3
revealed that the two zinc fingers can wrap around a single GATA site or bridge between
two sites on different DNA molecules.79
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GATA2 Gene Structure and Cis-Regulatory Elements
The mouse GATA2 is located on chromosome 6 spanning 8.5kb and can produce
two mRNA transcripts. The two transcripts differ in their 1st exon which contains part of
the 5’UTR (Figure 1-3A). The distal 1S exon is utilized in the hematopoietic and neural
tissues whereas the proximal 1G exon is utilized in all other tissues where GATA2 is
expressed.55,80 The remaining 5 exons are shared by both transcripts. Both the mRNA
transcripts finally result in production of the same 480 amino acid protein.
Cis-regulatory elements that control GATA2 expression in various tissues were
mapped using YAC and BAC clones containing GATA2 genomic sequences. The
d16YAC clone containing -198kb to +73kb region completely rescued the GATA2-/hematopoietic defect whereas the d27YAC clone containing -148kb to +73kb region did
not.81 This localized the hematopoietic regulatory elements between -198kb to – 148kb
region (Figure 1-3B). Even though the d16YAC rescued the hematopoietic defect these
transgenic pups die at P0 due to urogenital patterning defects.81 Two urogenital enhancers
were then mapped to +75kb (UG4) and +113kb (UG2) region using reporter gene
expression from BACs.82 Two intronic enhancer elements have been identified so far
(Figure 1-3A). A 190bp region in the intron 5 is required for GATA2 expression in the
V2 interneurons in the spinal cord.83 A 480bp region in the intron 4 drives GATA2
expression in the HSCs, vascular and lymphatic endothelial cells.84,85
Additional cis-regulatory elements called “GATA switch sites” were identified
using Chromatin immunoprecipitation studies in G1E cell line (Figure 1-3B). GATA1
binds to 5 dispersed regions in the GATA2 locus (-77kb, -3.9kb, -2.8kb,-1.8kb and
+9.5kb relative to the 1S promoter) and repress GATA2 transcription.86-88 The same
regions were previously bound by GATA2 when it is actively expressed suggesting a
positive feedback loop. Targeted deletion of the -1.8kb region reactivates GATA2
transcription in late stage erythroblasts where it is normally repressed resulting in an
erythroid maturation defect.89 Targeted deletion of the -2.8kb region reduced GATA2
expression in LT-HSCs and MPPs of fetal liver without affecting their numbers.90
GATA2 Functions during HSC Specification
GATA2 functions have been studied using conventional knockout, conditional
knockout and overexpression approaches. Tsai et al. generated the first GATA2
conventional knockout mice by replacing the exon5 which encodes the 2nd zinc finger
with the neo cassette.66 The GATA2 knockout mice die at E10.5 due to severe anemia.
Yolk sac of these mice had fewer hematopoietic cells (3 fold reduction), and made lesser
CFU-C colonies.53,66 However the erythroid differentiation was normal. These data
demonstrate that primitive hematopoiesis is defective upon GATA2 removal. Defects in
the definitive hematopoiesis were much more profound. Since the mice die at E10.5
definitive hematopoiesis was studied in chimeras generated by injecting GATA2-/- ES
cells into wild-type blastocysts. GATA2-/- ES cells did not contribute to any aspects of
definitive hematopoiesis (fetal liver, adult BM, thymus, spleen and peripheral blood).
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Figure 1-3. GATA2 gene structure and cis-regulatory elements.
(A) The GATA2 locus has 6 exons. The 5’ and 3’ untranslated region (UTR) is shown in
black. Arrows indicate the transcription start sites from the 1S and 1G exons. The
location of the two intronic enhancers is shown in blue. V2: V2 interneuron enhancer,
VE: vascular and lymphatic endothelial cell enhancer. (B) Diagram of the entire GATA2
locus on chromosome 6 showing location the of different enhancer elements. Position of
the d16 and d27 YAC constructs is shown in reference to the GATA2 locus. The 2
urogenital enhancers UG4 and UG2 are shown in blue. Locations of GATA switch sites
are indicated by downward arrows.
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These data suggested that GATA2 is required for the generation of HSC/progenitor cells.
The GATA2+/- mice are viable with normal blood counts.91 However the number
of HSCs in the AGM region and adult BM generated is lower than wild type mice. In the
AGM region of the GATA2+/- mice there are lesser Sca1+ cells and lesser reconstitution
when transplanted into sub lethally irradiated recipients.92 In the adult BM there are fewer
CD34- LSK cells and a competitive repopulation defect into lethally irradiated recipients
has been reported.91 Thus the generation of definitive HSCs is also affected in a dose
dependent manner by GATA2.
More recently it has been shown using a conditional knockout approach that
GATA2 is also essential for the generation of the fetal liver HSCs and maintenance of the
adult HSCs. Cre mediated GATA2 excision at E9-E11 reduced the number of phenotypic
and functional HSCs in the E14.5 fetal livers in a dose dependent manner.85 GATA2
inactivation in the adult BM also reduced the number of phenotypic HSCs.85 Effects on
the functional HSCs and progenitor compartments could not be addressed because of the
VE-cre which was not expressed in progenitors. When the embryonic lethality at E10.5
was surpassed in the conditional knockout, a lymphatic patterning defect was also
identified.85
GATA2 Functions during Differentiation and Self-Renewal
After HSCs are specified it appears that GATA2 downregulation is required for
differentiation and self-renewal. Expression of GATA2 mRNA is highest in HSCs
followed by progenitor cells and completely absent in mature cells.52,93,94 Enforced
expression of GATA2 using a retroviral vector in wild type murine BM resulted in a loss
of hematopoietic progenitor derived colony formation.95 GATA2 expressing Lin- Sca1+
cells (HSCs) did not expand in the BM of transplant recipients and these primitive cells
did not contribute to long term multilineage reconstitution.95 Even the cells expressing
GATA2 during short term reconstitution had progressively decreasing levels of GATA2
over time.95 Similar effect was also seen upon enforced expression of GATA2 in human
cord blood cells transplanted into NSG mice.96
GATA2 downregulation can be mediated by the antagonistic action of other
lineage specific transcription factors. This has been demonstrated in erythroid and
myeloid lineages where the lineage specific transcription factors GATA1 and PU.1
downregulates GATA2. G1E cell line is derived from in vitro differentiation and
immortalization of GATA1-/- ES cells.97 G1E cells are arrested in the pro-erythroblast
stage due to loss of GATA1 and they express high levels of GATA2.49,98 Upon
restoration of GATA1, GATA2 is downregulated and these cells can differentiate into
mature erythroid cells.97,98 GATA1 downregulates GATA2 expression by displacing
GATA2 at 5 regions in the GATA2 locus itself (-77kb,-3.9kb, -2.8kb,-1.8kb, +9.5kb) and
disrupting its positive feedback loop.98 Similarly PU.1-/- hematopoietic progenitors from
fetal liver can be cultured in vitro and upon restoration of PU.1 can differentiate into
macrophages by down regulating GATA2.99
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GATA2 also downregulates the lineage specific transcription factors in progenitor
cells. This has been observed in G1ME cells which is another cell line derived from
GATA1-/- ES cells. The G1ME cells are arrested in the MEP stage due to absence of
GATA1. Interestingly in the G1ME cells GATA2 binds to the PU.1 locus preventing its
expression.100 Accordingly, knockdown of GATA2 in G1ME cells resulted in upregulation of PU.1 and macrophage differentiation.
The only mature lineage which requires constant GATA2 expression is the mast
cells. Requirement of GATA2 in this lineage was identified when GATA2-/- yolk sac
cells could not be differentiated in vitro into mast cells in the presence of SCF.53 GATA2
is also highly expressed in proliferating mast cells.101 GATA2 expression can
differentiate PU.1 rescued hematopoietic progenitors into mast cells.99 GATA2 can also
instruct GMP cells into mast cells when CEBPa is suppressed.102 GATA2 has also been
shown to instruct eosinophil and basophil differentiation from GMPs upon sequential
expression with CEBPa.102 However it is not clear whether GATA2 is required in these
lineages since GATA1 is also expressed in eosinophils and basophils and GATA1 is
required for the generation of the eosinophil lineage. GATA2 overexpression has also
been reported to expand megakaryocytes and also implicated in Down’s Syndrome
AMKL associated with a GATA1short isoform.103-105
GATA2 Effects on Cell Cycle
GATA2 has also been shown to mediate cellular quiescence. GATA2 expression
is higher in the quiescent HSCs than the cycling HSCs.96 It is possible that the
downregulation of GATA2 brings the HSCs into cell cycle during differentiation and
self-renewal. In myeloid cell lines (32D, BaF3 and FDCP Mix), enforced expression of
GATA2 using a conditional GATA2-ERT system mediates quiescence. The mechanism
proposed was GATA2 down-regulates c-myc, resulting in decrease in Cul1 and Skp2 (E3
ubiquitin ligase complex) and accumulation of p21/p27 cell cycle inhibitors.106 It was
also shown in BaF3 cells that this quiescent state is reversible upon removal of the ligand
tamoxifen.
GATA2 Chromatin Occupancy
Two studies have reported the GATA2 chromatin occupancy in HSCs and
Progenitor cells (HSPCs) .Wilson et al. did chromatin immnoprecipitation followed by
deep sequencing (CHIP-SEQ) of GATA2 and 9 other transcription factors in a murine
hematopoietic progenitor cell line HPC-7.107 In this study GATA2 binding regions
significantly overlapped with that of other transcription factors SCL, LYL1, LMO2, and
RUNX1. In addition these five transcription factors were found frequently at ERG and
FLI-1 binding sites. Together these 7 transcription factors form the “HSC heptad” and
their targets were enriched for genes expressed in HSCs. Li et al. did CHIP-SEQ of
GATA2, SCL and Ldb1 in primary lineage negative murine bone marrow cells.108 Ldb1,
an adapter protein was bound to all the genes which were occupied by GATA2 and SCL.
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This suggests that Ldb1 is an important part of the complex containing GATA2 in
HSPCs.
GATA2 binding sites during differentiation of erythroid cells and megakaryocytes
have been studied extensively using Chip assays on G1E and G1ME cell lines. Both the
cell lines are derived from in vitro differentiation of GATA1 null ES cells.97,109 G1E cells
are arrested in the pro-erythroblast stage and G1ME cells are arrested in Megakaryocyte
Erythroid Progenitor stage. Upon GATA1 rescue both G1E and G1ME cells differentiate
into mature erythroid and megakaryocytes respectively. Both G1E and G1ME cells
initially have high expression of GATA2 and downregulate it as they differentiate due to
GATA1 rescue. Chromatin immunoprecipitation studies during this process have
revealed that GATA1 displaces GATA2 from binding sites in target genes. This
phenomenon is called as “GATA switch” leads to altered transcription of the target
genes.110 GATA switch sites were identified in genes like β-globin, GATA2, c-kit111,
Lyl1112, PU.1100 and mir144/451 microRNA cluster.113 Few examples are show below.
In the β-globin locus of G1E cells, the initial GATA2 binding results in low level
globin expression.114 Upon GATA1 rescue, GATA1 displaces GATA2 resulting in high
level globin expression during erythroid differentiation. In the c-kit and GATA2 loci, the
initial GATA2 binding results in active transcription of these progenitor genes. GATA2
is shown to co-occupy with SCL in these loci. During the GATA switch GATA1 replaces
GATA2 and the SCL occupancy is lost resulting in transcriptional repression. In the PU.1
locus, GATA2 is co-occupied with FOG-1 resulting in transcriptional repression of a
myeloid gene. During GATA switch, GATA1 replaces GATA2 interacting with FOG-1
and resulting in further repression and reinforcing erythroid differentiation. Other
myeloid transcription factors like MpO, CEBPα and Hhex were also bound by GATA2
and repressed in G1ME cells.104 Knockdown of GATA2 in G1ME cells results in
myeloid trans-differentiation underscoring the importance of this GATA2 mediated
repression of myeloid genes in the MEP.100 GATA2 also binds to and upregulates mast
cell genes in G1E cells which is shut off after GATA switch.115
ChIP-Seq analysis of K562 cell line have identified GATA2 binding to the locus
of co-repressor ETO-2.76 In G1E cells GATA2 binding and activation of ETO-2 was
confirmed. Interestingly upon GATA1 rescue, ETO-2 binds and represses its own locus
facilitating GATA1 mediated differentiation. ChIP-Seq analysis on G1ME cells identified
co-occupancy of GATA2 and ETS-1 transcription factor.116 This study also pointed out
that GATA2 binding sites were enriched in the regions within genes and especially in
the1st intron.116
ChIP-PCR analysis of several GATA sites in G1E cells showed that GATA2
binds only to a small proportion of WGATAR motif in complex with an E-Box motif
(SCL binding site).117 High percentage of GATA2 bound sites were also bound by SCL
and have a specific epigenetic signature. The GATA2 bound sites were associated with
acetylated histones H3 and H4 that were dimethylated at H3K4 and H3K36, and devoid
of H3K9 trimethylation.117
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GATA2 Mutations in Acute Myeloid Leukemia
GATA2 mutations were reported in several syndromes associated with
predisposition to AML and MDS (Table 1-2). Hahn et al reported two GATA2 missense
mutations (T354M and T355del) associated with familial MDS and AML.118 These
mutations were heterozygous in the affected individuals and there was incomplete
penetrance among family members. The T354M mutant showed dominant negative
effects and the T355del mutant show loss of function in in vitro experiments (reporter
assays, cell lines). The T354M mutation was also reported in two other syndromes with
similar clinical features called the MonoMAC syndrome and the DCML syndrome. Both
the syndromes were characterized by monocytopenias, B-cell and NK cell deficiency,
mycobacterial and HPV infections with predisposition to MDS and AML. There were
several other overlapping mutations between these two syndromes (Table 1-2). Most of
the missense mutations are located in the 2nd zinc finger of GATA2. Others include Nterminal frame-shift mutations resulting in pre-mature stop codons and complete
deletions of the 2nd zinc finger. Using exome sequencing Ostergaard et al identified
GATA2 mutations in a disease of primary lymphedema associated with MDS /AML
called the Emberger syndrome.119 The mutations did not overlap with previous diseases
which show that the lymphatic defects require a different set of mutations. Activating
mutations of GATA2 were also found in CML blast crisis phase. Recently sequencing of
the genome of pediatric non-Down’s syndrome Acute Megakaryocytic leukemia
(AMKL) patients identified GATA2-HoxA9 fusion. In this fusion GATA2 N-terminus
lacking the zinc-fingers was fused to the homeodomain of the transcription factor
HoxA9. So far none of the GATA mutations have been reintroduced into mice to test if
they cause the disease.
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Table 1-2.

GATA2 mutations in myeloid neoplasms.

Syndromes
Familial MDS/AML
MonoMAC
syndrome

Amino Acid
Changes
T354M
T355del

Clinical Features

R398W

Monocytoopenia
Hsu et al.120
B and NK cell
deficiency
Mycobacterial and
Papilloma virus
infection
Predisposition to MDS
and AML

T354M
G81fs
N371K
R361delRNAN
M1del290
R396W
R396Q
D259fs
N317fs
P254L
Δ340-381

References

Predisposition to MDS Hahn et al.118
and AML

Dickinson et al.121

DCML syndrome

G200fs
T354M
R398W
Δ340-381

Same as MonoMAC
syndrome

Emberger syndrome

L105Pfs
R78Pfs
R337X
A341Pfs
C373R
R361L
A194Sfs

Primary lymphedema Ostergaard et al.119
Cutaneous warts
Deafness
Predisposition to MDS
and AML

CML blast crisis

L359V
Δ341-346

Blast crisis in CML

Pediatric AMKL

GATA2-HoxA9 Non Down’s
fusion
syndrome AMKL
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Zhang et al.122
Gruber et al.123

CHAPTER 2.

MATERIALS AND METHODS
Vector Construction

Construction of the inducible GATA2-ERT vectors
MSCV-GATA2iresGFP and MSCV-iresGFP gamma-retroviral constructs have
been described previously.95 To generate the MSCV-GATA2-ERTiresGFP vector, the
human GATA2 cDNA was cloned into the MSCV-ERTiresGFP vector, which contains
the ligand binding domain of the ERT estrogen receptor variant (G521R) which is
responsive only to Tamoxifen.124 The GATA2 fragment was released from the
MSCV-GATA2iresGFP vector (NcoI digest) and ligated upstream of mutant ERT (EcoRI
digest) after Klenow fill-in. This cloning strategy removed the stop codon and the last
aminoacid (G) from GATA2 cDNA and generated a 7 aminoacid linker (NSDPRNE)
between GATA2 and ERT. The GATA2-ERTiresGFP fragment was then moved from
the gamma retroviral to the lentiviral pCL10.1 GFP vector using EcoRV and NotI sites to
generate the pCL10.1-MSCV GATA2-ERTiresGFP vector.125 The lentiviral vector was
only used to generate the GATA2-ERT transgenic mice. All other experiments were
performed with the gamma retroviral vector.
Construction of the GATA2 DNA binding mutants
The wild type human GATA2 cDNA was first transferred to pUC19 Shuttle
vector for subsequent site-directed mutagenesis. MSCV GATA2-ERT retroviral construct
was cut with EcoRI to release the hGATA2 cDNA fragment (1.4 kb). The pUC19 vector
was linearized with EcoRI and ligated to the above hGATA2 fragment to generate the
pUC19 GATA2 vector .The mutagenic primers were designed using the QuickChange
primer Design application from Agilent Technologies. Wildtype reverse primers were
designed to run in the opposite direction starting from the mutagenic primer. The
following primers with 5 ' phosphorylation were utilized: C352P (Forward,
5’- AGCCGGCACCTGTTGTGCAAATCCTCAGACGACAAC-3’; Reverse,
5’- CTTCTGGCGGCCGACAGTCTTCGC-3’), C370P (Forward,
5’- CGGGGACCCTGTCCCCAACGCCTGTGGC-3'; Reverse,
5’- TTGGCGTTTCGGCGCCATAAGGTG-3').
The pUC19 GATA2 plasmid was linear amplified with the desired mutations
using the Phusion Hot Start II DNA Polymerase (Thermo Scientific). Then the plasmid is
then circularized by ligation and transformed into NEB Turbo Competent E.Coli .The
pUC19- GATA2 mutants were sequence verified using the following sequencing primers:
5’- GGCTCGTTCCTGTTCAGAAG-3', 5'-CTTCTCCAAGACGCCACTGC-3'). The
mutant Zinc finger domains were then switched between the retroviral vectors MSCVGATA2-ERTiresGFP and MSCV-GATA2iresGFP from the pUC19-GATA2 vectors
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using SacII and BamHI sequential digests .The mutant retroviral vectors were sequence
verified again using the above primers before vector production.
The pCDNA3.1 constructs containing the wild type and mutant GATA2 and
GATA2-ERT cDNA were generated for in vitro transcription and translation for the
EMSA assays. The pCDNA3.1-GATA2 constructs were generated by cloning of the
GATA2 fragment from the retroviral vectors using EcoRI and EcoRV enzymes .Then the
pCDNA3.1-GATA2-ERT constructs were generated by replacing the GATA2
C-terminus region of the pcDNA3.1-GATA2 vector with the GATA2 C-terminus ER
from each of the retroviral GATA2-ERT vectors .SacII and EcoRV was used for the
pcDNA3.1-GATA2 vector. SacII and ClaI (blunt) was used for the inserts from the
MSCV-GATA2-ERT vectors.
Construction of a lentiviral mir30 based shRNA vector
LMP-RFP vector (MSCV-mir30PGK-puroiresRFP), a retroviral mir30 based
shRNA vector was a kind gift from the Dr. Richard Gilberson's lab. The LMP-RFP
vector is a derivative of the LMP vector from Gregory Hannon’s Lab.126 The “PGK puro
ires” fragment was replaced with the "PGK" fragment from the pCL-c-MNDU3 PGK
GFP vector using the BlpI and NcoI restriction sites. The RFP reporter was replaced with
PCR amplified m-cherry cDNA .The m-cherry cDNA was PCR amplified from the
pCL20-MSCV-CreERT2-Ires-mCherry vector using the following primers: m-cherry
Forward,5’- GTGAGCAAGGGCGAGGAGGATA-3’; m-cherry Reverse (ClaI)
5’-TTTTTTATCGATGCTACTTGTACAGCTCGTCCA-3’.The entire mir30 cassette
with m-cherry reporter was then moved to the lentiviral backbone of pCL20cGFP vector
using ClaI and EagI sites.127 Finally an XhoI site outside the viral LTR was removed to
generate the pCL20c-mir30mcherry vector .This vector was used for direct single step
cloning of the hairpins in the future.
Cloning of the hairpins targeting genes of interest into the pCL20c mir30 m-cherry
vector
The 137 bp sequences containing the hairpins were designed using the shRNA
psm2 Design from the Greg Hannon Lab website
(http://katahdin.cshl.org/siRNA/RNAi.cgi?type=shRNA). 3-5 oligonucleotides were
designed for each of the gene targets (Table 2-1) and single strand template PCR was
performed as described previously.128 The PCR products were digested using EcoRI and
XhoI sites and ligated into the unique XhoI and EcoRI sites in the pCL20c-mir30mcherry
vector. VSV-G pseudotyped lentiviral vector particles were prepared using a 4-plasmid
system using transient transfection of 293T cells, as previously described below.
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Table 2-1.

Primers used for mir30 based short hairpin cloning.

Name
5'miR30PCRxhoIF
3'miR30PCREcoRI
F
Sequencing primer
shNmyc
shHoxA9
shGFP
NS

Sequence
5’-CAGAAGGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCG-3’
5’-CTAAAGTAGCCCCTTGAATTCCGAGGCAGTAGGCA-3’
5’-CCCTTGAACCTCCTCGTTCGACC-3
5’-TGCTGTTGACAGTGAGCGACCTGGCGAGCTGATCCTCAAGTAGTGAAGCCACAGATGTACTT
GAGGATCAGCTCGCCAGGCTGCCTACTGCCTCGGA-3’
5’-TGCTGTTGACAGTGAGCGCGGAGTTTCTGTTTAACATGTATAGTGAAGCCACAGATGTATACA
TGTTAAACAGAAACTCCTTGCCTACTGCCTCGGA-3’
5’-TGCTGTTGACAGTGAGCGAGCACAAGCTGGAGTACAACTATAGTGAAGCCACAGATGTATAG
TTGTACTCCAGCTTGTGCCTGCCTACTGCCTCGGA-3’
5’-TGCTGTTGACAGTGAGCGATCTCGCTTGGGCGAGAGTAAGTAGTGAAGCCACAGATGTACTT
ACTCTCGCCCAAGCGAGAGTGCCTACTGCCTCGGA-3’

The “sense-loop-antisense” regions of the 97bp “mir30-like “DNA oligonucleotides are highlighted in “blue-red-blue” format. The
5’miR30PCRxhoIF and 3’miR30PCREcoRIF were used to perform single strand template PCR “NS” denotes non-silencing vector.
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Vector Production and Titration
Lentviral vector production
We seeded 293T cells at about 15×106 cells per 10 cm plate in the morning. Six
hours after plating the cells, lentiviral helper plasmids and the vector plasmids were
transfected using calcium phosphate method. The amounts of the plasmids used per
10 cm plate are Vector – 10 µg; GP1-1 – 6 µg; RTR2 – 2 µg and VSVG – 2 µg. Ten
plates were transfected at a single time. In a 50 ml conical tube, plasmids required for 10
plates were mixed with 500 µl of calcium phosphate and water to a total volume of 5 ml.
Then 5 ml of 2× HSBSS solution was added drop by drop while continuously vortexing
the tube. The tube was then allowed to sit for 10-15 minutes. One ml of the transfectant
was added to each of the 10 cm plates and mixed by tilting .The plates were incubated
overnight and media was replaced with DMEM and 10% Fetal Bovine Serum (FBS).
Twenty four hours after replacing the media the virus supernatant was collected from the
plates and pooled. The supernatant was filtered through a 0.22 micron filter (Steriflip) to
remove any cell debris. Aliquots of the filtered virus supernatant were then flash frozen
in dry ice and stored at -80°C. A small aliquot was taken to titer the virus at this time on
293T cells.
Retroviral vector production - transient prep
We seeded 293T cells at about 8×106 cells per 10cm plate in the morning. Six
hours after plating the cells, retroviral helper plasmids and the vector plasmids were
transfected using calcium phosphate method as described above for the lentiviral
production. The amounts of the plasmids used per 10cm plate are Vector- 10 µg, Old gag
pol- 5 µg, VSVG- 1 µg. The transfected plates were incubated overnight and media was
replaced with DMEM and 10% Fetal Bovine Serum (FBS). Forty eight hours after
replacing the media the virus supernatant was collected from the plates and pooled .The
supernatant was filtered through a 0.22 micron filter (Steriflip) to remove any cell debris.
The virus supernatant was stored in ice and used for transduction of GPE-86 producer
cells in the following days.
Generation of GPE-86 producer cells
We seeded 0.5×106 GPE-86 cells in a 10 cm plate. After 6 hours 5 ml of the
media was removed and replaced with 5 ml of viral supernatant with polybrene. Every 12
hours the media was replaced with 5 ml of viral supernatant and 5 ml of fresh media. The
transduction was carried out for 7 days and then evaluated by flow cytometry. Usually
more than 90% of producer cells were transduced at this time and they were frozen down
for future retroviral production.
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Retroviral vector production from GPE-86 producers
The producers were thawed and split at least 3 times before collecting the virus.
Virus supernatants were collected 48 hours after the media change .The supernatants
were filtered and frozen down in -80°C. A small aliquot is taken to titer the virus at this
time on 3T3s.
Vector titration
We seeded 293T or 3T3 cells at a concentration of 0.5×106 cells per 10 cm plate.
Six hours after seeding increasing amounts of the lentiviral or retroviral supernatant was
added to each of the plates. The plates were transferred to a CO2 incubator. After 4 days
the cells were lifted using trypsin and percentages of GFP positive cells (GFP %) were
analyzed using Flow Cytometry. The virus titer represented as Transducing units /ml
(TU/ml) is calculated using the following formula.

Isolation of Bone Marrow Cells and Transduction
Mice
The GATA2-ERT transgenic mice were generated by transduction of murine
blastocysts with lentiviral pCL10.1 MSCV GATA2-ERTiresGFP vector supernatants.
The GATA2-ERT transgenic mice were routinely identified by measuring the GFP
marking in lymphoid and myeloid cells of peripheral blood. All the other experiments
were performed on 8 -12 weeks old female C57Bl/6 mice (Jackson Laboratories, Bar
Harbor, ME). All experimentation with mice was performed under protocols approved by
the Institutional Animal Care and Use Committee of St Jude Children’s Research
Hospital.
Isolation and transduction of lineage depleted mouse BM cells
Bone marrow was harvested from 8 to 12 weeks old female C57BL/6J mice (The
Jackson Laboratory, Bar Harbor, ME). Mice were sacrificed in the CO2 chamber and then
rinsed with 70% Ethanol. Tibiae and femurs were dissected out removing the muscles
and skin tissues. The ends of these bones were trimmed using scissors. The bone marrow
was then flushed with 2% FBS in PBS using a 25 G needle for the femur and 27 G needle
for the tibia. The bone marrow collected from all the bones was then flushed one more
time using the 19 G needle and then filtered through 40 µ filter. The cells were then
counted using methylene blue and 1% acetic acid to exclude the RBCs. The cells were
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spun down in the centrifuge at 1200 rpm for 10 minutes. After removing the supernatant
by suction the cell pellet was resuspended in AutoMACS buffer (40 µl per 107 cells). The
biotin antibody cocktail which contains biotinylated antibodies against mouse CD5,
CD45R (B220), CD11b (Mac1), Gr-1 (Ly6G/C), 7-4 and Ter-119 was then added (10 µl
per 107 cells). The cells were mixed well and incubated at 4°C for 10 minutes. This was
followed by addition of AutoMACS buffer (30 µl per 107 cells) and anti-biotin
microBeads (20 µl per 107 cells). The beads were mixed well and incubated for an
additional 15 minutes at 4°C. The cells were washed by adding more AutoMACS buffer
(2 ml per 107 cells) and centrifuged at 1200 rpm 10 minutes. After removing the
supernatant by suction the cell pellet was resuspended in AutoMACS buffer (3 ml for
2X108 cells). The lineage depleted cells were separated using the AutoMACSTM separator
using the "depletes" setting. The purity of these cells was tested by staining the cells for
c-kit and anti-biotin antibodies followed by flow cytometry and consistently achieved 9599% purity.
The lineage depleted cells were prestimulated for two days in the presence of
20 ng/ml recombinant mouse IL-3, 50 ng/ml recombinant human IL-6 and 50 ng/ml
recombinant mouse SCF (PeproTech) and Dulbecco's modified Eagle medium (DMEM)
supplemented with 15% fetal bovine serum (FBS), 100 units/ml penicillin, 100 µg/ml
streptomycin, 2 mM L-glutamine (R&D systems, Minneapolis, MN). After
prestimulation the cells were transferred into plates coated with 25 ug/ml of retronectin
(Takara, Madison, WI).The viral supernatant was added at multiplicity of infection
(MOI) between 1.5 - 3 every 12 hours. After four rounds of transduction the cells were
lifted from the retronectin coated plates by scraping. The cells were directly transplanted
into lethally irradiated recipients or cultured for an additional 48 hours before performing
in vitro experiments.
Isolation and transduction of 5-FU treated bone marrow cells
We advocated 5-FU intra-peritoneally to mice at a dose of 150 mg/kg. Two days
after 5-FU administration bone marrow was isolated, filtered and counted as described
above. The bone marrow cells were plated at a concentration of 2×106 cells/ml with
DMEM and 15% FBS and cytokines (IL-3 – 20 ng/ml , IL-6 50 ng /ml , SCF 50 ng/ml )
for prestimulation. After 24 hours of prestimulation the cells were lifted by scraping and
counted. We plated 20×106 cells in retronectin coated 15 cm plates with virus supernatant
and fresh media containing cytokines and protamine sulphate. Every 12 hours the media
was replaced with fresh viral supernatant. Four transductions were carried out by this
method. Six hours after the last transduction the cells were lifted by scraping and
transplanted into lethally irradiated recipient mice. A small fraction of cells were cultured
for another 48hrs and assessed for bulk transduction by flow cytometry.
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Transduction of GATA2-ERT and GFP cell lines with the lentiviral shRNA vectors
We transduced 1×106 cells with the viral supernatant at a MOI of 15-20 in
retronectin coated 6-well plates. The cells were transduced every 24 hours for a total of
three hits. One day after the last transduction the cells were lifted and re-plated into
suspension plates. After 48 hours the m-cherry % was determined and the liquid culture
started.
Functional Assays
Bone marrow transplantation
Transduced BM cells were harvested and either diluted with untransduced cells or
kept undiluted in PBS with 2% FBS. Female C57Bl/6 mice between 10 to 12 weeks of
age were given a total body irradiation of 1125 cGy from a 137Cs source (J.L. Shepherd,
San Fernando, CA, USA). We injected 2.5×106 cells in a volume of 0.5 ml as a single
dose by tail -vein injection to each recipient. All the transplant recipients received antibacterial prophylaxis (Baytril 2.27% solution Bayer) for three weeks post transplantation.
Peripheral blood analysis on the recipients was performed at 8, 12, 16 and 20 weeks posttransplant.
Liquid culture
The liquid culture experiments were initiated 48 hours after the last transduction.
Cells were lifted from the plates and counted. The percentages of the transduced cells
were determined by flow cytometry. For the in vitro competition experiments the
transduced cells were diluted with mock cells to start at a uniform GFP percentage of
20%. For the knockdown experiments no dilution was performed. Cells were plated at a
starting concentration of 3.3×105 cells/ml. Every 3 days the cells were counted,
percentages of transduced cells were measured by flow cytometry and replated again at
3.3×105 cells/ml. The cells were cultured in DMEM with 15% FBS and cytokines
(murine IL-3 20 ng/ml, human IL-6 50 ng/ml and murine SCF 50 ng/ml).
Colony assay
Fifteen ml conical tubes containing three ml aliquots of Methocult GF M3434
(Stem Cell Technologies) were thawed at room temperature or 37°C water bath. For
plating primary colonies 0.3 ml cell suspension containing 3.75×103 cells was added to
the 3ml of M3434 media. The tube was vortexed and allowed to stand for 5 minutes to
dissipate the bubbles. Total volume of 1.1ml media containing cells was dispensed into
two 35 mm plates using a 16 gauge blunt needle and 3cc syringe. After 7 days the plates
were counted in a microscope with 4× objective for total colonies and GFP positive
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colonies. For subsequent re-plating the colonies were disrupted into single cell
suspension by adding 2.5 ml of DMEM and flushing through a 19G needle. The cells
were washed using 30 ml of DMEM and spun down at 1200 rpm for 10 minutes. The
cells were resupsended in a smaller volume (0.5 -1ml) and counted. The cells were
replated at 2.5×104 cells / plate and counted for colonies after 7 days.
Cell cycle assays
GATA2-ERT cell lines cultured with 100 nM Tamoxifen or Ethanol were stained
for DNA content using propidium iodide (PI) at the time points indicated. One million
cells were spun down, washed once with PBS and lysed in one ml hypotonic solution
containing PI and detergent (0.05 mg/ml propidium iodide, 0.1 % (w/v) sodium citrate,
0.1 % (v/v) Triton X-100) by vortex. Samples were then treated with DNAse-free RNAse
(Calbiochem cat # 556746) for 30 minutes at room temperature. Samples were then
filtered through 40u mesh and analyzed by flow cytometry. We also performed cell cycle
analysis on the shRNA vector transduced GATA2-ERT cell lines by incubating with
Hoechst 33342 at 10 µg/ml for 1 hour followed by FACS analysis. ModFit Analysis
(Verify Software House) was performed on total population (PI method) or select gated
population (Hoechst method).
Flow cytometry and cell sorting
Single-cell suspensions were prepared from thymus and bone marrow (femoral
and tibial bones) by passage through a 70-micron cell strainer (BD). Cells were
resuspended in PBS with 2% FCS. About 70 µl of blood was obtained from mice by
retro-orbital puncture and RBC lysis was performed with BD FACS Lyse Wash
Assistant. Cells were stained for 30 min with fluorochrome-conjugated or biotinconjugated antibodies. Cells were then washed with excess medium and were
resuspended in PBS with 2% FCS containing a dead cell marker (PI or DAPI) or stained
again with secondary antibodies. FACSCalibur, LSR and LSRII (BD Biosciences), were
used for flow cytometry and BD Aria (BD Biosciences) was used for cell sorting. For
sorting LSK cells, BM from GATA2-ERT transgenic mice was enriched for Sca1 and
c-kit markers using anti-PE, anti-APC magnetic beads in AutoMACS before staining
with Lineage-PECy7 antibodies. For sorting individual progenitor and stem cell
populations BM from C57Bl/6 mice were lineage depleted as described above prior to
staining with other progenitor and stem cell markers. Antibodies used are shown in Table
2-2.
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Table 2-2.

Antibodies used for flow cytometry and cell sorting.

Epitope
CD3e
CD3c
B220
Mac1
Gr-1
CD34
FcγR
Sca1
c-kit
CD127
Streptavidin
CD44
CD25
CD4
CD8a
Ter119
FcεR1

Clone
145-2C11
17-A2
RA3-6B2
M1/70
RB6-8C5
RAM34
2.4G2
E13-161.7
2B8
A7R34
1M7
PC61
L3T4
53-6.7
TER119
MAR-1

Conjugate
APC
PE
eFlour605 , PEcy7
APC-Cy7 , Alexa-700 , PE-Cy7
APC, APC-Cy7, PE-Cy7
PE
Alexa-700
PE, Biotin
APC, APC-Cy7
APC
PE Texas Red , PE-Cy7
PE-Cy7
APC
APC-Cy7, PE-Cy7
Alexa700, PE-Cy7
PE-Cy7
Biotin
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Company
BD
BD
BD
BD
BD
BD
BD
BD
BD
BD
BD
BD
BD
BD
BD
BD
Ebioscience

Imaging
Giemsa staining
We pelleted 5×104 cells in a 1.5 ml tube and resuspended them in 150 µl of PBS
in 2% FBS. The cytoslide (Thermo Scientific # 59910052) was setup against the
cytofunnel (Thermo Scientific #1102548) and locked using the cytoclip (Thermo
Scientific # 59910052). The cell suspension was then loaded into the cytofunnel and spun
in the Cytocentrifuge at 1000 rpm for 5 minutes (Cytospin 3 - Shandon cytocentrifuge).
The cytoslide was removed from the cytoclip and stained by dipping into a staining jar
containing Wright Giemsa Solution (CS434 Fisher) for 1 min. The cyotoslide was then
washed by dipping in distilled water 3 times 1 min each. The slide was then dried
overnight and the coverslip was mounted after adding a drop of Cytoseal 60 (Thermo
scientific). Images were taken using a Nikon microscope in 20× objective or 40 × oil
objectives respectively.
Immunostaining and confocal microscopy
Coverslips (22 X 22-1 Fisherbrand) were placed in 6-well plates and coated with
retronectin for 2 hours at room temperature. Retronectin coated coverslips were washed
once with PBS and incubated with cells at 37°C for 40 minutes. After cell attachment the
coverslips were washed twice with PBS and fixed with 4% paraformaldehyde for 30
minutes. Coverslips were washed again twice with PBS and permeablized with 0.1%
Triton X-100 for 15 minutes. Edges of the coverslips were then dabbed in paper and
blocked with Fx-signal enhancer (Invitrogen) for 30 minutes. All antibodies were
prepared in 10% normal goat serum in PBS. Coverslips were incubated with primary
antibody (1:50) overnight at 4°C. Coverslips were washed three times by dipping in
beakers containing PBS. Secondary antibody (1:50) was incubated 1 hour at RT. After 3
washes coverslips were incubated with 0.2 µg/ml of DAPI for 10 minutes. After wash
with water the coverslips were mounted into glass slides (Fisherbrand Superfrost Plus)
using Prolong Gold with DAPI mounting media (Invitrogen). Slides were cured overnight
at room temperature. Edges were secured by applying nail polish and visualized in Zeiss
LSM 510 NLO Meta confocal microscope. Antibodies used are shown in Table 2-3.
Molecular Techniques
RNA isolation and real - time PCR
When the starting cell numbers was more than 0.5×106 cells, Ribopure Kit
(Ambion AM1924) was used to extract RNA. RNAqueous-Micro Kit (Ambion AM1931)
was used when the starting cell numbers was less than 0.5×106 cells. RNA extraction was
performed according to the kit protocols. The RNA concentration and purity was
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Table 2-3.

Antibodies used for immunostaining (IHC) and western blot (WB).

Name

Dilution

Company

αGATA2

1:1000 (WB) ,
1:50 (IHC)
1:1000 (WB) ,
1:100 (IHC)
1:200 (WB)
1:25000 (WB)
1:1000 (WB)
1:10,000 (WB)
1:10,000 (WB)

Santa Cruz

Catalog
Number
sc-9008

Santa Cruz

sc-542

Santa Cruz
Millipore
Cell Signaling
Santa Cruz
Jackson
ImmunoResearch
Jackson
ImmunoResearch
Invitrogen

sc-6216
MAB374
#2555
sc-2004
115-035-062

Jackson
ImmunoResearch

711-075-152

αER alpha
αLamin B
αGAPDH
αGFP
Goat anti-rabbit HRP
Goat anti-mouse HRP
Rabbit anti-goat HRP Fc
Fragment specific
Goat anti-rabbit Alexa
Flour 555
Donkey anti-rabbit Texas
Red

1:10,000 (WB)
1:100 (IHC)
1:50 (IHC)
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305-036-008
A21429

determined by the NanoDrop 1000 UV-Vis spectrophotometer (Thermo Scientific). The
cDNA synthesis was performed using the Superscript VILO cDNA synthesis kit
(Invitrogen). Real time PCR was performed using TaqMan primer probe sets (Table 2-4)
and TaqMan Fast Universal PCR Master Mix, No AmpErase UNG (Applied
Biosystems). A cDNA template equivalent of 10ng was used for each reaction. The
amplification was carried out in the Step One plus Real-Time PCR System (Applied
Biosystems).
Affymetrix array hybridization
RNA purity and concentration was determined by using the NanoDrop 1000
UV-Vis spectrophotometer (Thermo Scientific). The integrity of RNA was determined by
electrophoresis analysis using Agilent 2100 BioAnalyzer Lab on a Chip System (Agilent
Technologies, Santa Clara, CA). The total RNA was processed by the Hartwell Center
Microarray Core by using the Affymetrix Eukaryote one-cycle target labeling protocol
(1 µg of total RNA) or the 3' IVT Express (100 ng of total RNA).The RNA was first
reverse transcribed using oligo dT primers containing T7 promoter followed by second
strand synthesis. The resulting cDNA was in vitro transcribed with biotnylated
ribonucleotides to generate the cRNA. The cRNA was hybridized to the 430v2 GeneChip
array at 45°C overnight. The arrays were then washed and stained with streptavidin -PE.
The arrays were scanned and an image file was produced. The expression values were
summarized using the MAS5 algorithm as implemented in the GCOS v1.4 software
(Affymetrix, Santa Clara, CA).
Total protein extraction using Laemelli buffer
One million cells were spun down and washed once with 1ml of PBS. The cell
pellet was then resuspended in 100 µl of ice cold PBS containing protease inhibitor
cocktail (Sigma-Aldrich P8340) and AeBSF (Gold Biotechnology) at a 100× dilution. To
the cell suspension 100 µl of 2× Laemmeli sample buffer (Bio Rad Laboratories)
containing beta mercaptoethanol (20×) was added and then boiled at 100°C for 5
minutes. The samples were then stored in -80°C before performing the immunoblot.
Table 2-4.

TaqMan primer probe sets used for RT-PCR.
Gene Name
mouse + human GATA2
mouse GATA2
mouse mycN
mouse hoxA9
mouse GAPDH

Catalogue Number
Mm00492302_g1
Mm00492300_m1
Mm00627179_m1
Mm00439364_m1
Mm9999915_g1

The primer probe sets were purchased from Applied Biosystems.
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Cell compartment extraction using the Qproteome cell compartment kit
The Qproteome cell compartment kit was purchased from Qiagen (Cat No
37502). Five million cells were spun down at 500 g for 10min at 4°C and washed twice
with ice cold PBS. Protease inhibitors and AeBSF (100×) were added to the buffers
(CE1, CE2 and CE3). The cell pellet was resuspended in 250 µl of buffer CE1 and
incubated for 10 minutes at 4°C in an end over shaker. After a 1000 g spin for 10 minutes
the supernatant containing the “cytoplasmic fraction " was extracted. The pellet was
again resuspended in 250 µl of buffer CE2 and incubated for 30 minutes at 4°C in an end
over shaker. After a 6000 g spin for 10 minutes the supernatant containing the
“membrane fraction " was extracted. Seven µl of benzonase was added to the pellet and
incubated for 15 minutes at room temperature followed by 250 µl of buffer CE3 for 10
minutes at 4°C in an end over shaker. After a 6800 g spin for 10 minutes the supernatant
containing the “nuclear fraction " was extracted. All the fractions were then stored in 80°C before performing the immunoblot.
Immunoblot
I added 2× Laemelli buffer containing beta-mercaptoethanol to the protein
extracts and boiled for 5 minutes at 100° C. The samples were loaded into NUPAGE
4-12 % Bis-Tris gel (Invitrogen) and run at 200V for 1 hour: 30 min with NUPAGE
MOPS SDS Running buffer. The gel was then transferred to PVDF membrane using
NUPAGE transfer buffer at 30V for 1 hour 30 min. The membrane was blocked with 5%
milk in TBS 0.1% - Tween 20 for 1 hour. The primary antibody was incubated overnight
at 4°C. After 3 washes with TBS-T the secondary antibody was incubated for 1 hour at
room temperature. After 3 washes with TBS-T the blot is developed using ECL prime
western blotting detection reagent (Amersham). Antibodies used and their dilutions are
shown in Table 2-3.
Electrophoretic mobility shift assay
Human wild type and mutant GATA2 and GATA2-ERT proteins were
synthesized from pCDNA3.1 expression plasmids using the Rabbit reticulocyte TnT kit
(Promega). Four hundred thousand counts per minute of P32 labeled double stranded
oligonucleotide containing the alpha globin promoter
(5'-GATCTCCGGCAACTGATAAGGATTCCCTG-3') were incubated with the protein
lysates in the presence or absence of 500 molar excess of unlabeled double stranded
oligonucleotides. Binding reactions contained 10 mM Tris, pH 8.0, 40 mM KCl, 0.05%
NP-40, 6% glycerol, 1 mM DTT, 0.2 g poly dI/dC, 200 µM ZnCl2 and 5 µl of
synthesized GATA2 and GATA2-ERT lysates. Samples were incubated at 4°C overnight
and resolved by electrophoresis through a nondenaturing 4% polyacrylamide gel in 0.5
TBE (45 mM Tris-borate, 1 mM EDTA) at room temperature and analyzed using the
Storm 860 phosphoimager (Molecular Dynamics, Sunnyvale, California).
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T4 kinase labeling reaction and annealing reactions
The alpha-globin reverse oligo nucleotides were 5' end labeled using the T4
Polynucleotide kinase kit (Promega M4101). The labeled oligos were purified using
Illustra TM ProbeQuant G-50 Micro Columns (GE Healthcare 28-9034-08). The Reverse
and forward oligonucleotides were annealed in 50mM MgCl2 and 100 mM Tris pH 8.0
by boiling for 10 minutes followed by slow cooling to Room temperature overnight.
TnT reactions
In vitro transcription and translation was performed using the TnT T7 quick
coupled transcription/translation system (Promega # L1170). Two small scale reactions
containing 2 µg of the pCNDA3.1 constructs in a 50 µl reaction was setup with either the
cold methionine or S35 labeled methionine. The S35 labeled protein lysates was run on a
4-12 % Bis-Tris gel (Invitrogen) to verify the presence of the GATA2 and GATA2-ERT
proteins. The unlabeled protein lysates were used in the EMSA assay.
Chromatin immunoprecipitation
GATA2-ERT cells were harvested and stained with Gr-1-PE antibody and
enriched for Gr-1 negative population by FACS sorting. 20×106 cells were crosslinked
for 10 minutes by adding formaldehyde to a final concentration of 1%. The reaction was
quenched by adding glycine to a final concentration of 0.125 M for 5 minutes. The fixed
cells were washed twice with ice cold PBS and the cell pellet was snap frozen in dry ice
with protease inhibitors and AeBSF. The cell pellet was later thawed and resuspended in
2 ml of cell lysis buffer (10 mM Tris pH 8.0, 10 mM NaCl, 0.2% NP-40 in water) with
protease inhibitors and AeBSF for 10 minutes on ice. After a spin of 2500 rpm for 10
minutes the nuclei pellet is resuspended in 800 µl of Nuclei Lysis Buffer (50 mM Tris pH
8.0, 10 mM EDTA, 1% SDS in water) and sonicated. The sonication was done with 1.5
ml microfuge tubes containing 200 µl aliquots in Bioruptor UCD-200 (Diagenode) for 30
cycles (30s “ON” and 30s “OFF” at 200W). This resulted in a shearing size between 200
bp to 700 bp. The sheared chromatin was diluted with 5× IP dilution buffer (20 mM Tris
pH 8.0, 2 mM EDTA, 150 mM NaCl, 1% Triton X-100, 0.01% SDS in water) and spun
down at 14000 rpm for five minutes to remove any undissolved nuclear material. Two µg
of a rabbit polyclonal GATA2 antibody (sc-9008, Santa Cruz) or isotype matched
preimmune IgG (ab37415, Abcam) was added to each 200 µl of chromatin and incubated
overnight at 4°C in a rotator platform. No antibodies were added to a 200 µl aliquot
which was used as input control. The chromatin was incubated for an additional 4 hours
with 20 µl of Protein A Dynabeads (#100.01D Invitrogen). The beads containing
immune-bound chromatin were collected by placing the microfuge tubes on a magnetic
stand. The beads were washed three times with wash buffer (1 part nuclei lysis buffer + 4
parts IP dilution buffer) and then resuspended with 200 µl of elution buffer (100 mM
NaHCO3, 1% SDS in water). Reverse crosslink was performed at 65°C overnight in the
presence of Proteinase K. Finally the supernatant containing immunoprecipitated DNA
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was pooled from several reactions and further purified using QIAquick PCR Purification
Kit (#28104, Qiagen) according to the kit protocols. Quantitative Real Time PCR is
performed using SYBR green method with primers indicated on Table 2-5.
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Table 2-5.

Primers used in quantitative chromatin immunoprecipitation assay.
Locus Name
α-globin promoter
Gata2 (-) 1.8 kb
Gata2 (-) 2.8 kb
Gata2 (-) 3.9 kb
Gata2 1G promoter
Gata2 1S promoter
necdin

Forward Sequence
TGACCAAGGTAGGAGGATACTAACTT
GCATGGCCCTGGTAATAGCA
GCCCTGTACAACCCCATTCTC
GAGATGAGCTAATCCCGCTGTA
AGATACCCAGAAGGTGCACGTC
CCCCTCGAAGTGATGTCGAA
GGTCCTGCTCTGATCCGAAG

Reverse Sequence
TTGCCCGGACACACTTCTTAC
CAGCCGCACCTTCCCTAA
TTGTTCCCGGCGAAGATAAT
AAGGCTGTATTTTTCCAGGCC
GCAGACCCTGCACCCCT
TCTGGCTGTCTCTCGGTTCC
GGGTCGCTCAGGTCCTTACTT

mycN -2.2kb
mycN -9.8kb
mycN +.6kb
mycN +2.3kb
mycN +3kb
mycN +3.2 kb
mycN 6.5kb

ACACCTGTGCTCTTCACT
CACCCTGGCCCTTAGAAG
GCAGCCGTGACCTACATT
GTGTTTCCAGCCTCTTCTGT
CACAGCCCCATGGAAAAAAA
AAGTGCAGGCTTATCACCAA
GCGTGTCTGGCATTTGAG

AGGTCCAAGGAAGATAAACGA
AGAGCAGAGAAGAAAGGGAAAG
CGCGGGGAAAGAAGGAAAA
TGCTGCGTTCCCTTTGTT
CTACCACTGCCGCTCCTAA
CCAGCCCCCCTATTAGAC
CCCTGCCCAGATGATTCT

HoxA9 -3.8kb
HoxA9 -1.2kb
HoxA9 -15bp
HoxA9 + 2kb
HoxA9 +3.8 kb
HoxA9 +7.5kb
HoxA9 +8.5kb
HoxA9 +5.6kb control

GTGGTGGACAGGATAAAATGGA
AATGGCAGAGAAGAGTTGGAG
AACCGCTCTGGTATCCTT
CGGGTCTCCGCTCTACTC
GCATCCCGGAGAACTATCT
AGCCCAGACCCAGTTTTT
AAACCCGACTTCACAATGGA
GCTCACACAAATCCCATTCCA

GCTGTGCGTGGAAAAAGA
GCACTGCCTGAGACCACA
GGAGGGAGGGGAGTAACAA
ATGGGTGCCTCTGGATCT
GGAGAGAAGCTGTGGCATAA
ACAGGAAACGGAGGAAACAA
AGCCTGGACCCACTGAAA
CTTTCTCGCCGCCATCTC
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CHAPTER 3.

RESULTS

Downregulation of GATA2 Expression during Hematopoiesis in the Adult BM
To monitor GATA2 expression during hematopoiesis we first isolated murine
hematopoietic stem cells and various progenitor cells based on cell surface marker
expression by FACS Sorting. The Kit+ Sca1+ Lin- CD150+CD48- population (SLAM) is
highly enriched for Long Term HSCs (LT-HSCs) in which one in 2.1 cells (47%) yield
long-term multilineage reconstitution in irradiated mice.129 The Kit+ Sca1+ Lin- (LSK)
population is a heterogeneous population of both short term reconstituting (ST-HSCs),
long term reconstituting HSCs (LT-HSCs) and multipotent progenitors (MPPs). The Kit+
Sca1- Lin- population is devoid of stem cell activity and can be fractionated into Common
Myeloid Progenitor (CMP), Granulocyte Monocyte Progenitor (GMP) and
Megakaryocyte Erythroid Progenitor (MEP).130 The Common Lymphoid Progenitor
(CLP) is present in the Kitlow Sca1low Lin- CD127+ population.131 BM isolated from 10
C57BL/6 mice was pooled and sorted into the populations described above and lysed for
RNA (Figure 3-1A). Based on quantitative RT-PCR analysis we found that GATA2
expression was highest in the LT-HSCs (Figure 3-1B). The heterogeneous LSK
population had 1.5 fold lower expression than the LT-HSCs due to the presence of lower
expressing ST-HSCs (Figure 3-1B). In the progenitor compartment GATA2 expression
was downregulated more in the CLP (12 fold) than the myeloid progenitors (2.4-3.3 fold)
(Figure 3-1B). The least expression was seen in the mature Lin + cells (20 fold) (Figure
3-1B). In summary downregulation of GATA2 expression is seen during hematopoietic
differentiation and myeloid progenitors have higher GATA2 expression than the
lymphoid progenitors.
GATA2-ERT Expressing BM Cells Exhibit TAM Independent GATA2 Function in
CFU-C Assays
Previous studies from our lab have demonstrated that bone marrow progenitors
and stem cells subjected to enforced expression of GATA2 from a retroviral vector show
a complete loss of colony forming activity in vitro and a loss of repopulating ability in
vivo95. We developed an inducible GATA2-ERT vector in which the protein would be
cytosolic in the absence of Tamoxifen (TAM) and with the addition of TAM enters into
the nucleus thus allowing regulated GATA2 activity in response to Tamoxifen (Figure
3-2A). The GATA2-ERT vector was first tested for TAM-induced reduction in colony
forming activity. Bone marrow cells transduced with the MSCV GATA2 ires GFP and
MSCV GATA2-ERT ires GFP vectors showed similar GATA2 expression at the mRNA
level compared to the control MSCV ires GFP vector transduced and untransduced BM
cells (Figure 3-2B). The transduced BM cells were then plated in methylcellulose media
for colony assays in the presence or absence of 100 nM Tamoxifen. Consistent with our
previous results, the proportion of GFP + colonies formed in the GATA2 group was 8
fold lower than the control GFP group irrespective of the Tamoxifen treatment (Figure
3-3A). GATA2-ERT transduced BM cells in the absence of Tamoxifen formed colonies
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Figure 3-1. Endogenous GATA2 expression in various stem and progenitor
compartments of the adult BM.
(A) Pooled BM from 10 mice is depleted of lineage markers (Ter119, Gr1, Mac1, CD4,
CD8, B220, and NK1.1) and then stained for progenitor and stem cell markers (Panel 1CD34, ckit, Sca1, FcγR and CD117; Panel 2 – ckit, Sca1, CD150, CD48). Detailed gating
strategy used for sorting various compartments for subsequent RNA extraction is shown.
(B) GATA2 expression levels in sorted stem and progenitor compartments relative to
total BM using quantitative RT-PCR and TaqMan primer probe sets. GAPDH was used
as the endogenous control.
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Figure 3-2. Successful transduction of murine BM cells with the inducible
GATA2-ERT retroviral vector.
(A) Schematic of the MSCV based retroviral vectors used in the study (NF= N-terminus
zinc finger, CF= C-terminus zinc finger). The vectors contain an internal ribosomal entry
site (ires) that allows cap independent translation of the GFP coding sequence. Thus
transgene GATA2-ERT dose in individual cells can be predicted based on GFP
expression (Mean Fluorescence Intensity). The aminoacid sequences of the linker region
connecting human GATA2 and the ERT in the MSCV GATA2-ERT vector is also
shown. (B) Quantitative RT-PCR analysis of gene expression of total GATA2 (mouse &
human) in lineage depleted BM cells 2 days post-transduction with the above vectors.
GAPDH was used as the endogenous control.
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Figure 3-3. GATA2-ERT expressing cells exhibit TAM independent GATA2
function on myeloid CFU-C assays.
(A) Bone marrow cells transduced with MSCV-iresGFP, MSCV-GATA2iresGFP and
MSCV-GATA2-ERTires GFP vectors were plated in semisolid media (Methocult
M3434) in the presence of 100 nM Tamoxifen or equivalent volume of Ethanol. 7 days
later total and GFP +ve primary colonies were counted to calculate the percentage of GFP
+ve CFU-C (n=3). (B) Representative images of primary colonies in the absence of
Tamoxifen. (C) CFU-Cs from MSCViresGFP and GATA2-ERTiresGFP and mock
transduced BM cells were tested for serial replating ability (n=3). Total colonies were
scored, harvested and re-plated every 7 days after plating. Cells were plated at 5X103 per
plate in the primary plating followed by 2.5X104 per plate for secondary and tertiary
plating respectively.
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similar in number to the control GFP vector transduced cells. However, in the presence of
100 nM Tamoxifen there was a 13-fold reduction in the GATA2-ERT colonies, an effect
similar to the GATA2 vector. Surprisingly the sizes of the GATA2-ERT colonies in the
absence of Tamoxifen were consistently larger than the mock and control GFP vector
colonies (Figure 3-3B). To test if this larger colony size is associated with increased
self-renewal activity we tested the GATA2-ERT vector against the control vector in a
serial colony replating assay. Cells harvested from primary colonies of GATA2-ERT
transduced cells were able to consistently generate four-fold higher secondary colonies
than the GFP transduced cells (Figure 3-3C). When replated for tertiary colonies, only
the GATA2-ERT transduced cells retained cells with colony forming, clonogenic
potential.
GATA2-ERT Vector Immortalizes Primary BM Cells into Myeloid Cell Lines
Given the effect of GATA-2ERT expression on endowing serial replating
potential on hematopoietic progenitors, we next tested whether expression would have
effects on cells propagated in vitro liquid cultures. Transduced BM cells were cultured in
DMEM with 15% FBS in the presence of IL-3, IL-6 and SCF. Under these culture
conditions normal untransduced BM cells cease to proliferate at 3- 4 weeks becoming
mast cells.132 GATA2-ERT transduced bone marrow cells showed greater proliferation
compared to the GFP transduced and untransduced cells (Figure 3-4A) frequently
resulting in the establishment of immortalized cell lines (6 out of 7 experiments). Wright
Giemsa stains indicated that the GATA2-ERT immortalized cell lines were composed of
immature myeloid cells with some spontaneous differentiation (Figure 3-4B). This was
further confirmed by FACS analysis, which showed that the 50% of cells are Gr1+
Mac1+ in these cell lines compared to the controls which become mast cells expressing
ckit+ FcER1+ (Figure 3-4C). Only once the control GFP vector immortalized BM cells
(1 out of 7 experiments) resulting in a GFP cell line. All of these immortalized cell lines
are IL-3 dependent (data not shown). Upon treatment with 100 nM of Tamoxifen all the
GATA2-ERT cell lines stopped proliferating (Figure 3-5A) similar to the CFU-C assays.
Cell cycle analysis showed cell cycle arrest with increased G0/G1 phase as early as 24
hours post TAM treatment in GATA2-ERT cell lines (Figure 3-5B). Thus, in the
presence of TAM, the GATA2-ERT vector behaves as a wild type GATA2.
Low Nuclear Concentration Achieved by the GATA2-ERT Vector in the Absence of
TAM
The increased proliferation and colony forming ability of the GATA2-ERT vector
in the absence of Tamoxifen could be the result of low levels of GATA2-ERT entering
the nucleus which has been reported in other inducible vectors like mycER and
creER.133,134 To test this hypothesis, subcellular protein fractionation was performed on
untreated, Tamoxifen (100 nM) and Ethanol (vehicle) treated GATA2-ERT cell lines.
GATA2-ERT protein was detected in both the nuclear and cytoplasmic fractions of
untreated and vehicle treated cells confirming the activity of the GATA2-ERT vector in
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.
Figure 3-4. GATA2-ERT immortalizes primary BM cells into myeloid cell lines.
(A) Growth curves of lineage depleted BM cells transduced with MSCV-GATA2ERTiresGFP and MSCV-iresGFP vector compared with untransduced cells. Cells were
counted at the time points indicated by trypan blue exclusion method. Results are shown
as mean ± SD for 3 independent experiments. (B) Wright-Giemsa stained cytospin slides
at day 27 under light microscopy. (C) FACS analysis at day 28 after staining for mast cell
markers (c-kit, FcεRI) and myeloid markers (Gr-1, Mac-1).
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Figure 3-5. Effects of the absence and presence of Tamoxifen on GATA2-ERT cell
lines.
(A) Growth curves of GATA2-ERT and GFP cell lines treated with 100 nM Tamoxifen
(TAM) or an equivalent volume of Ethanol (EtOH). (B) Cell cycle analysis of GATA2ERT and GFP cell lines treated with 100 nM TAM or EtOH. At 24 and 48 hours posttreatment cells are lysed with Propidium Iodide and analyzed by flow cytometry. Results
are shown as mean ± SD of experiments on 3 different GATA2-ERT cell lines and 1 GFP
cell line.
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the absence of Tamoxifen (Figure 3-6A). Upon treatment with 100 nM Tamoxifen,
GATA2-ERT protein was detected only in the nuclear fractions showing complete
nuclear translocation. Thus GATA2-ERT translocation in the absence of Tamoxifen
could achieve a low level tonic activity in the nucleus, 3-fold lower than with complete
translocation with Tamoxifen as measured by densitometry analysis using ImageJ
software. To independently confirm these results we also did immunostaining on
untreated and TAM treated GATA2-ERT cell lines (Figure 3-6B) and retroviral
packaging cells (Figure 3-7) followed by confocal imaging. In the absence of TAM both
these cells showed nuclear GATA2-ERT protein staining which co-localized with DAPI.
Upon TAM treatment, the intensity of the nuclear GATA2-ERT signals increased
demonstrating further nuclear translocation. The cytoplasmic GATA2-ERT signals in the
absence of TAM could only be visualized in the packaging cells but not in the GATA2ERT cell lines possibly due to the presence of thin cytoplasm in these cells. These data
confirm the low nuclear concentration achieved by the GATA2-ERT vector in the
absence of TAM.
Distinct Progenitor and Mature Cell Populations Are Present in GATA2-ERT Cell
Lines
When GATA2-ERT cell lines and the randomly immortalized GFP cell lines were
stained for c-kit and Gr-1 markers, three different populations were consistently observed
(Figure 3-8A). These populations were named P1 (c-kit+Gr-1- ), P2 (c-kit-Gr-1- ) and P3
(Gr-1+) respectively. Upon Wright- Giemsa staining P1 and P2 populations showed an
immature phenotype with large nucleus and thin cytoplasm whereas the P3 population
showed mature granulocytes with segmented nuclei (Figure 3-8B). When these
populations were sorted from GATA2-ERT cell lines and then cultured for 7 days, the
highest proliferation was observed in P1 followed by P2 and the lowest proliferation seen
in P3 (Figure 3-8C) . In 7 days sorted P1 cells can generate P2 and P3, P2 cells can
generate only P3 and finally P3 cells did not generate other populations (Figure 3-8A, D
and E). Taken together, the above data show that GATA2-ERT cell lines are organized as
a hierarchy with the progenitor P1 cells differentiating into an intermediate P2 cells and
finally becoming the mature P3 cells.
Myeloid Immortalization Is GATA2-ERT Dependent
To confirm if the GATA2-ERT immortalized cell lines are indeed dependent
upon the low level tonic GATA2 activity we examined the effects of GATA2-ERT
knockdown in three independently immortalized GATA2-ERT cell lines. We used a
mir30 based shRNA containing lentiviral vectors carrying m-cherry as a reporter (Figure
3-9A). Because a single mRNA transcript is generated from the MSCV GATA2-ERT ires
GFP vector for the production of both GATA2-ERT and GFP proteins we tested
GATA2-ERT knockdown using a shRNA targeting GFP (shGFP). After transduction
with shGFP vector, mcherry + ve transduced cells showed an 80% GATA2-ERT protein
knockdown compared to mcherry –ve untransduced cells (Figure 3-9B). The shGFP
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Figure 3-6. Subcellular localization of GATA2-ERT before and after treatment
with TAM in GATA2-ERT immortalized cell lines.
(A) Subcellular localization of GATA2-ERT protein in GATA2-ERT cell lines after
treatment with 100 nM TAM or ethanol for 3 hours compared with untreated cells.
Proteins from GATA2-ERT cell lines (WCL) were sub-fractionated into cytoplasmic
(Cyto) and nuclear (Nuc) and western blotted for GATA2-ERT, GAPDH (cyto) and
Lamin B (Nuc). GATA2-ERT protein was detected using an anti-ER antibody. (B)
GATA2-ERT and GFP cell lines were attached retronectin coated coverslips in the
presence of 100 nM TAM or EtOH for 12 hours then fixed and stained. Red represents
GATA2-ERT (1°-αGATA2, 2°- α-rabbit Alexa Flour 555) and blue represents DAPI.
Top row shows GATA2-ERT staining and bottom row shows an overlay with DAPI.
Imaging was performed using Zeiss LSM 510 Meta point scanning confocal microscope
with a Plan Apochromat 63X/1.4 Oil objective and zoom scan of 1.3.
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Figure 3-7. Subcellular localization of GATA2-ERT in GPE-86 producer cells.
GPE-86 GFP and GATA2-ERT cells were attached to Poly-D lysine coated glass bottom
dishes overnight and then treated with 100 nM TAM/Ethanol for 24 hours before fix and
stain. Red represents GATA2-ERT (1°-αGATA2, 2°- α-rabbit Texas Red) and blue
represents DAPI. Top row shows GATA2-ERT staining and bottom row shows an
overlay with DAPI. Imaging was performed using Nikon C1Si laser scanning confocal
microscope with a Plan Apochromat 60.0X/1.45/.13 Oil objective.
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Figure 3-8. Distinct progenitor and mature cell populations are present in
GATA2-ERT cell lines.
(A) Representative FACS Analysis of unsorted GATA2-ERT cell line and sorted P1, P2
and P3 populations after 7 days in culture, showing the ability of the sorted populations to
regenerate the starting cell line. (B) Wright Giemsa stains on cytopsins of sorted P1, P2,
P3 populations and P3 population after 7 days in culture. (C) Growth curves of the sorted
populations during the 7 days in culture. (D) Data from Figure 3-8A represented as bar
graphs comparing the frequencies of different populations. (E) Data from a second
experiment performed on another independently generated GATA2-ERT cell line
showing the existence of a hierarchy.
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Figure 3-9. GFP targeting vector effectively knocks down GATA2-ERT protein
levels.
(A) Schematic of the mir30 based lentiviral shRNA vector used in the study. MSCV
promoter drives the mir30 based shRNA and PGK promoter drives the reporter mcherry
expression. Location of the EcoRI and XhoI sites used for cloning 137bp hairpins is also
shown. (B) GFP targeting vector effectively knocks down GATA2-ERT protein levels.
Three GATA2-ERT cell lines and a GFP cell line were transduced with shRNA vectors
targeting GFP sequence (shGFP) or a scrambled sequence (NS). 3 days post-transduction
mcherry + and mcherry - cells were sorted and lysed for proteins and western blotted
against GATA2-ERT (α-ER alpha), GAPDH and GFP.
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vector transduced cells grew faster than untransduced cells in liquid culture as shown by
a progressive reduction in m-cherry% in the shGFP group over an 18 day period (Figure
3-10A and B). On the other hand when GATA2-ERT cells were transduced with the
control non silencing vector (NS) both transduced and untransduced cells showed a
similar GATA2-ERT protein expression (Figure 3-9B) and equal proliferation in liquid
culture with a stable m-cherry% over an 18 day period (Figure 3-10A and B). When the
GFP cell line with similar myeloid characteristics to the GATA2-ERT cells was
transduced with the shGFP and NS vectors there were no changes in proliferation
excluding other toxic effects of microRNA expression in myeloid cells (Figure 3-10A
and B). To identify the nature of the growth defect associated with GATA2-ERT
knockdown we looked at the cell cycle, cell death and differentiation of the GATA2-ERT
cell lines after transduction with the shGFP vector. There was no increase in dead cells in
these cultures based on trypan blue staining (data not shown). However cell cycle
analysis using Hoechst staining showed a decrease in cycling cells after GATA2-ERT
knockdown (Figure 3-11). This also correlated with the increase in P3 differentiated cells
in these cultures (Figure 3-12A, B and C). These data demonstrate that expression of
GATA2-ERT remains essential for self-renewal and proliferation of the myeloid
progenitors after immortalization and loss of GATA2-ERT leads to their rapid
differentiation into non-cycling ,Gr1 expressing, mature cells.
Screening of Genes Involved in GATA2-ERT Mediated Immortalization
Gene expression analysis was performed to identify genes differentially regulated
between three independently generated GATA2-ERT cells lines compared to the GFP
cell line which does not express GATA2. A total of 1861 probesets showed a greater than
2-fold difference between each of the GATA2-ERT cell lines vs. the GFP cell line.
Among them, 995 probesets were increased and 866 probesets were decreased. Estrogen
receptor1 (Esr1) probeset was on the top of the list with a 500 fold average fold
difference. Since the human GATA2 cDNA is fused to the estrogen receptor ligand
binding domain in the vector we expected to see high expression of the Esr1 probeset.
Gene ontology and pathway enrichment analysis was performed using DAVID
bioinformatics databases. Differentially regulated genes were grouped into genes
regulating cell proliferation (143 probsets, Table 3-1), hematopoiesis (57 probesets) and
apoptosis (100 probestes). Top 10 upregulated and downregulated genes in these lists are
shown in Tables 3-1, 3-2 and 3-3. Myeloid leukemia related genes like HoxA9, Nmyc
and Bcl11a were found to be significantly up-regulated in the microarray. Real time PCR
analysis using TaqMan primers confirmed that Nmyc was 50-fold up regulated and
HoxA9 was 2400-fold up regulated in the GATA2-ERT cell lines (Figure 3-13A).
HoxA9 and Nmyc Knockdown Partially Recapitulates GATA2-ERT Loss in
Immortalized Cell Lines
The knockdown approach described above was used to test if HoxA9 or Nmyc is
required for GATA2-ERT mediated proliferation. The vectors designed for knockdown
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Figure 3-10. Knockdown of GATA2-ERT inhibits proliferation of the
immortalized cell lines.
(A) GATA2-ERT knockdown inhibits proliferation of GATA2-ERT immortalized cell
lines. FACS analysis of GFP and mcherry expression in GATA2-ERT and GFP cell lines
transduced with shGFP and NS vectors at different time points in liquid culture. Cells
were also stained with Hoechst for simultaneous cell cycle analysis. Transduction with
shGFP vector results in a GFP low mcherry+ population (Quadrant 1) compared to GFP
high mcherry+ (Quadrant 2) population in NS transduced cells. (B) Summary of the
percentages of mcherry+ cells from above and 2 other GATA2-ERT cell lines.
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Figure 3-11. Knockdown of GATA2-ERT inhibits proliferation of the
immortalized cell lines due to G0/G1 cell cycle arrest.
Cell cycle analysis using Hoechst was performed on GATA2-ERT cell lines (n=3) at
day2 and day7 post transduction with the NS and shGFP targeting vectors. Cell cycle
effects on GATA2-ERT cells transduced with shGFP (quadrant 1, Q1) were compared
with NS transduced cells (quadrant 2, Q2) and untransduced cells (quadrant 3, Q3) in
both groups. The location of the quadrants was shown in Figure 3-10A.
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Figure 3-12. Knockdown of GATA2-ERT inhibits proliferation of the
immortalized cell lines due to differentiation.
(A) Representative FACS Plots of GATA2-ERT and GFP cell lines transduced with the
non-silencing (NS) and GFP silencing (shGFP) shRNA vectors and Mock transduced
cells 6 days post- transduction. (B) Summary of the frequencies of different populations
from above and 2 other GATA2-ERT cell lines (n=3). (C) Frequencies of different
populations from the above GFP cell line (n=1).
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Table 3-1.
Genes differentially expressed in GATA2-ERT vs. GFP cell line (cell
proliferation).
Gene Symbol
Esr1
Mycn
Arrdc4
Cd28
Il6st
S1pr1
Pawr
Fgf6
Trim24
Sox2
Tnfrsf9
Mab21l1
Il2ra
Tnfsf10
Hes1
Angptl2
Fgf3
Arnt2
Il2ra
Mab21l1

Description
estrogen receptor 1 (alpha)
v-myc myelocytomatosis viral related oncogene,
neuroblastoma derived (avian)
arrestin domain containing 4
CD28 antigen
interleukin 6 signal transducer
sphingosine-1-phosphate receptor 1
PRKC, apoptosis, WT1, regulator
fibroblast growth factor 6
tripartite motif-containing 24
SRY-box containing gene 2
tumor necrosis factor receptor superfamily, member 9
mab-21-like 1 (C. elegans)
interleukin 2 receptor, alpha chain (probe 1)
tumor necrosis factor (ligand) superfamily, member 10
hairy and enhancer of split 1 (Drosophila)
angiopoietin-like 2
fibroblast growth factor 3
aryl hydrocarbon receptor nuclear translocator 2
interleukin 2 receptor, alpha chain (probe 2)
mab-21-like 1 (C. elegans)

Fold Change
500.3
59.7
20.2
17.5
16.0
14.9
14.9
9.6
9.2
9.0
-20.2
-21.1
-22.1
-26.0
-28.5
-35.1
-40.3
-45.3
-104.0
-165.0

Individual Fold changes of genes differentially expressed in three GATA2-ERT cell lines
compared to the GFP cell line. Differentially expressed genes involved in regulation of
proliferation (GO: 0042127) were shortlisted using DAVID bioinformatics databases
(http://david.abcc.ncifcrf.gov). Top 10 differentially regulated genes are represented
above.
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Table 3-2.
Genes differentially expressed in GATA2-ERT vs. GFP cell line
(hematopoiesis).
Gene Symbol
Hoxa9
Bcl11a
Cd28
Eomes
Hdac9
Clcf1
Ercc1
Satb1
Pbx1
Tgfbr2
Themis
Card11
Jag2
Gadd45g
Xrcc5
Kit
Bcl6
Cd74
Hbb-b1 ///
Hbb-b2
Hba-a1 ///
Hba-a2

Description
homeo box A9
B-cell CLL/lymphoma 11A (zinc finger protein)
CD28 antigen
eomesodermin homolog (Xenopus laevis)
histone deacetylase 9
cardiotrophin-like cytokine factor 1
Excision repair cross-complementing rodent repair
deficiency, complementation group 1
special AT-rich sequence binding protein 1
pre B-cell leukemia transcription factor 1
transforming growth factor, beta receptor II
thymocyte selection associated
caspase recruitment domain family, member 11
jagged 2
growth arrest and DNA-damage-inducible 45 gamma
X-ray repair complementing defective repair in
Chinese hamster cells 5
kit oncogene
B-cell leukemia/lymphoma 6
CD74 antigen (invariant polypeptide of major
histocompatibility complex, class II antigen-associated)
hemoglobin, beta adult major chain /// hemoglobin,
beta adult minor chain
hemoglobin alpha, adult chain 1 /// hemoglobin alpha,
adult chain 2

Fold Change
77.0
36.8
17.5
11.3
11.1
8.4
7.6
7.3
7.3
5.8
-6.8
-7.8
-7.8
-8.4
-11.8
-13.0
-14.9
-17.5
-26.6
-30.6

Individual Fold changes of genes differentially expressed in three GATA2-ERT cell lines
compared to the GFP cell line. Differentially expressed genes involved in regulation of
hematopoiesis (GO: 0030097) were shortlisted using DAVID bioinformatics databases
(http://david.abcc.ncifcrf.gov). Top 10 differentially regulated genes are represented
above.
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Table 3-3.
(apoptosis).
Gene Symbol
Esr1
Cd28
Itsn1
Uaca

Genes differentially expressed in GATA2-ERT vs. GFP cell line
Description
estrogen receptor 1 (alpha)
CD28 antigen
intersectin 1 (SH3 domain protein 1A)
uveal autoantigen with coiled-coil domains and
ankyrin repeats
clusterin /// similar to clusterin

Clu ///
LOC100046120
Excision repair cross-complementing rodent repair
Ercc1
deficiency, complementation group 1
ceroid-lipofuscinosis, neuronal 8
Cln8
kit ligand
Kitl
Eph receptor A7
Epha7
O-6-methylguanine-DNA methyltransferase
Mgmt
tumor necrosis factor (ligand) superfamily, member 9
Tnfsf9
tumor necrosis factor receptor superfamily, member 9
Tnfrsf9
B-cell leukemia/lymphoma 6
Bcl6
B-cell translocation gene 2, anti-proliferative
Btg2
CD74 antigen (invariant polypeptide of major
Cd74
histocompatibility complex, class II antigenassociated)
tumor necrosis factor receptor superfamily, member 9
Tnfrsf9
tumor necrosis factor (ligand) superfamily, member
Tnfsf10
10
prion protein
Prnp
granzyme B
Gzmb
interleukin 2 receptor, alpha chain
Il2ra
inhibitor of DNA binding 3
Id3

Fold Change
500.3
17.5
10.3
9.2
8.0
7.6
7.3
7.1
6.6
6.3
-13.3
-14.6
-14.9
-14.9
-17.5
-20.2
-26.0
-33.5
-97.0
-104.0
-143.7

Individual Fold changes of genes differentially expressed in three GATA2-ERT cell lines
compared to the GFP cell line. Differentially expressed genes involved in regulation of
apoptosis (GO: 0042981) were shortlisted using DAVID bioinformatics databases
(http://david.abcc.ncifcrf.gov). Top 10 differentially regulated genes are represented
above.
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Figure 3-13. HoxA9 and Nmyc knockdown partially recapitulates GATA2-ERT
loss in immortalized cell lines.
(A) Quantitative RT-PCR analysis of gene expression of Nmyc, hoxA9, endogenous (m)
and total (m+h) GATA2 in GATA2-ERT cell lines (n=3) and GFP cell line (n=1). Gene
expression is first normalized to GAPDH and represented as a ratio between GATA2ERT and GFP cell lines. (B) and (C) GATA2-ERT cell line was transduced with shRNA
vectors targeting Nmyc (shNmyc), hoxA9 (shHoxA9) and a scrambled sequence (NS). 3
days post-transduction mcherry + cells were sorted for total RNA extraction followed by
quantitative RT-PCR. Expression levels of Nmyc and hoxA9 after knockdown relative to
the scrambled vector is shown. GAPDH was used as the endogenous control. (D) and (E)
FACS Analysis of m-cherry percentages of GATA2-ERT cell lines transduced with the
respective shRNA vectors at different time points in liquid culture.
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of Nmyc and HoxA9 showed 60% knockdown efficiency in the GATA2-ERT cell lines
(Figure 3-13B and C). The well characterized shGFP and NS vectors were now used as
controls. GATA2-ERT cell lines were transduced with the knockdown vectors at a
similar MOI (50%-80% m-cherry + cells) and grown in liquid culture for 3 weeks. As
expected GATA2-ERT cells transduced with the shGFP vector show a significant growth
disadvantage compared to the non-silencing vector (NS) in liquid culture. Upon
GATA2-ERT knockdown there is a progressive decrease in the m-cherry % over the
18-day culture period (Figure 3-13D). During this time period the non-silencing vector
transduced cells showed no significant changes in m-cherry+ cells. Nmyc and HoxA9
knockdown also resulted in a progressive decrease in m-cherry+ cells but at slower rate
than the shGFP group. The m-cherry marking in the shNmyc group dropped slowly from
75% on day 2 to 40% on day 18 compared to the shGFP group where it dropped quickly
from 73% on day 2 to 10% on day 11 (Figure 3-13D). Similarly in another experiment
the m-cherry marking in the shHoxA9 group dropped slowly from 50% on day 2 to 30%
on day 21 compared to the shGFP group it dropped quickly from 57% on day 2 to 3% on
day 12 (Figure 3-13E). These results show that Nmyc and HoxA9 at least have a partial
role in GATA2-ERT mediated proliferation. The fact that the growth defects are not
complete can be explained by the lack of complete Nmyc and HoxA9 knockdown by
these vectors and also by compensation by other GATA2 targets.
Absence of GATA2-ERT Chromatin Occupancy in the Nmyc and HoxA9 Locus
Since Nmyc and HoxA9 have a partial role in GATA2-ERT mediated
proliferation; chromatin immunoprecipitation (ChIP) assays were performed to test
whether Nmyc and HoxA9 are direct targets of GATA2-ERT. Protein extraction from
GATA2-ERT cell lines under various non-denaturing conditions with protease inhibitors
resulted in the rapid proteolysis of the 83KD GATA2-ERT protein into smaller fragments
between 27KD to 40KD detected by an ER specific antibody (Figure 3-14A). Only when
the cells were lysed in denaturing conditions using Laemelli sample buffer could this
degradation be prevented. Since the GATA2-ERT cell lines contain Gr1+ granulocytes it
is possible that proteolytic enzymes in their granules could cleave GATA2-ERT protein
during extraction. When the GATA2-ERT cells were sorted into Gr1+ and Gr1populations the total GATA2-ERT protein expression was similar in all the population
under denaturing conditions (Figure 3-14B). When the proteins were extracted under
non-denaturing conditions we could see less proteolysis in the Gr1- population indicating
that the enzymes in the mature Gr1+ fraction cause the degradation (Figure 3-14B). The
degradation is even further reduced in the Gr1- cells when the cells were fixed with
formaldehyde and chromatin extracted (Figure 3-14C). So we extracted chromatin from
Gr1- GATA2-ERT cells and performed ChIP assays using a rabbit polyclonal antibody
against GATA2 (H-116 Santa Cruz) and normal rabbit immunoglobulins (IgG). We did
quantitative PCR on the immunoprecipitated DNA fragments using primers that amplify
known GATA2 binding regions in the GATA2 locus. The -3.9 kb, -1.8 kb and -2.8 kb
regions in the GATA2 locus were significantly enriched (25 fold, 9 fold and 6.5 fold)
confirming that the H-116 antibody effectively immunoprecipitates the GATA2-ERT
protein (Figure 3-15A). Inspection of the Nmyc and HoxA9 locus revealed several
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Figure 3-14. Elimination of the mature Gr1+ population in the GATA2-ERT cell
lines prevents protein degradation and improves yield.
Western blots under denaturing conditions using anti-ER antibody to test GATA2-ERT
protein degradation. Protein lysates were extracted from a G2ERT cell line under
different conditions described. (A) Proteins were extracted from GATA2-ERT cell lines
under non-denaturing conditions with reagents such as M-PER (Pierce #78501) and Cell
Lysis Buffer (Cell Signaling # 9803) or denaturing conditions with Laemelli and betamercaptoethanol in the presence of protease inhibitors (PI) and PMSF. GPE-86 Producer
cells expressing GATA2-ERT (positive) and GFP (negative) vectors were used as
controls. (B) Proteins were extracted from unsorted and sorted Gr1 positive (Gr1 pos) and
negative (Gr1 neg) populations under denaturing (Laemelli) and non-denaturing (MPER) conditions. (C) Fixed and sonicated chromatin samples were prepared from
unsorted and Gr negative populations were western blotted after reverse cross link.
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Figure 3-15. Absence of GATA2-ERT chromatin occupancy in the Nmyc and
HoxA9 loci.
Quantitative Chromatin Immunoprecipitation (Chip) Analysis was performed to measure
the GATA2-ERT occupancy in the GATA2 (A), Nmyc (B) and HoxA9 (C) loci in a
GATA2-ERT cell line. The ChIP was performed using a rabbit polyclonal GATA2
antibody (H-116, Santa Cruz) and as a negative control ChIP was also performed with
isotype matched preimmune IgG (IgG). The locations of the GATA2 binding sites tested
are indicated relative to the Transcriptional start site of the gene. The -1.8, -2.8 and -3.9
GATA2 binding sites are previously reported GATA2 binding sites and were used as
positive controls for the assay. The 1S and 1G alternate first exons of GATA2 and the
brain specific promoter (necdin) are previously reported non-GATA2 binding sites. We
also designed primers for a hoxA9 locus region which does not have WGATAR motif
(control) as an additional negative control.
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predicted GATA2 binding sites containing the consensus “WGATAR” sequence. In the
Nmyc locus we designed primers to test the regions which have 2 palindromic GATA2
sites together with E-Box motif (CANNTG) which is shown to have higher predictability
of GATA2 binding. In the HoxA9 locus we tested all the 7 predicted GATA2 binding
sites. Surprisingly there was no enrichment seen in any of the sites tested in the HoxA9
and Nmyc locus (Figure 3-15B and C). These results indicate that HoxA9 and Nmyc are
probably not direct targets of GATA2 but could be secondary or tertiary targets. It is also
possible that GATA2 binds to distal regulatory elements such as enhancers to regulate
Nmyc and HoxA9 expression.
Lymphoid Block and Myeloid Expansion in Recipients of GATA2-ERT Transduced
Cells
The effects of the GATA2-ERT protein expression on murine hematopoiesis was
studied by BM transplant studies. BM cells isolated from 5-FU treated mice were
transduced with the GATA2-ERT and control GFP vector at similar MOI. The
transduced cells were transplanted into lethally irradiated recipients in presence or
absence of four fold excess of competing mock cells. At 12 weeks post-transplant GFP
marking in the peripheral blood of recipients were analyzed by flow cytometry.
Recipients of undiluted control GFP vector transduced cells show similar GFP marking in
B220+ cells (58%±20), Thy1.2+ cells (58%±15) and Gr1+ myeloid cells (84%±17)
(Figure 3-16). In contrast the undiluted GATA2-ERT recipients show a very low GFP
marking in B220+ cells (8%±3) and Thy1.2+ cells (14%±1) with high marking in Gr1+
cells (91%±3).This data indicate that the GATA2-ERT expressing HSCs preferentially
differentiate into myeloid cells. The GFP mean fluorescence intensity in the B220+ cells
and Thy1.2+ cells of GATA2-ERT recipients were much lower than the myeloid cells
indicating that the cells which escape the lymphoid block have very low GATA2-ERT
expression) (data not shown). The recipients of the diluted GFP vector transduced cells
showed the expected lower percentages of GFP marking in all lineages compared to the
undiluted group (B-cells 6%±3, T-cells 15%±4, myeloid 28%±18). However the diluted
GATA2-ERT group still showed higher GFP marking in Gr1+ myeloid cells (82%±6)
even after four fold dilution with mock cells. None of the transplant animals developed
leukemia. These results demonstrate that GATA2-ERT provides a competitive advantage
to myeloid cells in addition to a block in lymphoid differentiation.
GATA2-ERT Blocks the Lymphoid Development after Common Lymphoid
Progenitors (CLPs) and also Expands the Granulocyte Monocyte Progenitors
(GMPs)
Having found that the GATA2-ERT expands myeloid cells and blocks lymphoid
differentiation the question remained as to the stage at which GATA2-ERT exerts its
effects in both lineages. To investigate this we used the GATA2-ERT transgenic mice
which were generated by lentiviral transduction of murine blastocysts. The GATA2-ERT
transgene carried in the mice is driven by the same MSCV promoter as the retroviral
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Figure 3-16. Lymphoid block and myeloid expansion in recipients of GATA2-ERT
transduced BM.
FACS analysis of GFP percentages in B220 + cells, Thy 1.2 + cells and Gr1 + cells in
peripheral blood of recipients 12 weeks post-transplant. Values are represented as Mean
± S.D .Total numbers of recipients in each group is as follows , GFP group (n=2),
GATA2-ERT group (n=6), GFP 1:4 group (n=7) and GATA2-ERT 1:4 group (n=10).
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vector used previously in the transplant experiments. Southern blot analysis revealed the
presence of 2 copies of the transgene (data not shown). Quite similar to the transplant
results, these mice consistently showed high GFP% in the Gr1+ and Mac1+ cells and
very low GFP% in the B220+ and CD3+ cells in their peripheral blood (Figure 3-17A).
The stem and progenitor cell compartments from the GATA2-ERT transgenic mice bone
marrow were analyzed for GFP expression. The Lin-Sca1+Kit+ (LSK) compartment had
35% GFP + cells which indicated that the GATA2-ERT transgene was frequently
inactivated by position-effect variegation during HSC specification (Figure 3-17A).
Presence of GFP marking in the CLP (70%±17) in bone marrow and its absence in
mature B220+, CD4+ and CD8+ cells in peripheral blood suggested a post-CLP block. In
the myeloid lineage there was a progressive increase in vector-expressing cells with
differentiation. The GMPs showed higher GFP% (72%±6) compared to the CMPs
(36%±4), suggesting that GATA2-ERT has a proliferative effect on the GMPs. To
identify the block in T-cell development we tested the GFP marking in thymocytes of
GATA2-ERT mice at different stages of differentiation. GFP + thymocytes were only
detected at the earliest DN1 stage (19%±5) which is lower than that of the CLPs in the
bone marrow (Figure 3-17B). These data suggest that T-cell development is blocked at a
pre-thymic stage and the few GATA2-ERT expressing cells which seed the thymus
remain in the DN1 stage.
To understand the molecular mechanisms behind the GATA2-ERT mediated
lymphoid block, global gene expression profiling of GATA2-ERT expressing and nonexpressing LSKs from transgenic mice was performed. Our analysis showed 157 probe
sets were up-regulated and 190 probe sets were down-regulated in the GATA2-ERT
expressing LSKs. Furthermore, Gene Set Enrichment Analysis showed down-regulation
of B cell differentiation, B-cell receptor signaling, IL7 pathways and primary
immunodeficiency related pathways (Figure 3-17C). Crucial regulators of lymphoid fate
(Vpreb1, Ebf1, IL7R, Rag1, Dntt, Btla, Rag2, Lef1, and Tcf1) were significantly downregulated in the GATA2-ERT expressing LSKs (Table 3-4).
DNA Binding Activity of GATA2-ERT Is Required for Myeloid Expansion and
Lymphoid Block
It was possible that the myeloid expansion and the lymphoid block could be
attributed either to the low level transcriptional activity of the nuclear GATA2-ERT or to
cytoplasmic GATA2-ERT titrating out transcription factors required for lymphoid fate
choice (Ikaros, EBF, E2A and Mef2c) by protein-protein interactions. To clarify the
contribution from these two different processes we developed DNA binding mutants of
GATA2-ERT and tested them in functional assays to ascertain whether the phenotypic
effects required DNA binding of GATA2-ERT. Two point mutations C352P and C370P
were made in the cysteine residues of the 2nd zinc finger of GATA2 which is critical for
DNA binding activity (Figure 3-18A and B). These mutations were designed based on
previous studies to disrupt the structural integrity of this zinc finger and thereby abolish
DNA binding activity.74,135,136 The C352P and C370P mutant proteins expressed at
similar levels to the wildtype GATA2-ERT protein in transduced bone marrow cells
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Figure 3-17. GATA2-ERT blocks lymphoid development after CLPs and also
expands GMPs.
(A) FACS analysis of GFP percentages in various lymphoid and myeloid progenitors and
mature cells from GATA2-ERT transgenic mice BM and peripheral blood (n=3). LSK=
Lineage-, Sca1+, c-Kit+; CLP = Lineage-, IL-7Rα+, Sca1 low, c-Kit low; CMP =
Lineage-, Sca1-, c-Kit+, FcγR intermediate, CD34 intermediate; GMP = Lineage-, Sca1-,
c-Kit+, FcγR high, CD34 high. (B) FACS Analysis of GFP percentages in thymocytes
from GATA2-ERT transgenic mice at various stages of differentiation (n=6). DN1= CD4
-, CD8 -, CD44 +, CD25 -; DN2= CD4 -, CD8 -, CD44 +, CD25 +; DN3= CD4 -, CD8 -,
CD44 -, CD25 +; DN4= CD4 -, CD8 -, CD44 -, CD25 -. (C) GSEA Analysis of gene
expression profile between GFP – vs. GFP + LSK cells from BM of GATA2-ERT
transgenic mice (n=3). For each experiment RNA is isolated from sorted GFP + or GFP –
LSK cells derived from pooled BM (7 GATA2-ERT transgenic mice per experiment).
Enrichment plots shown for selected down regulated gene sets identified by GSEA.
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Table 3-4.

Changes in gene expression in GATA2-ERT expressing LSKs.

Gene Symbol
Vpreb1
Igll1
Ebf1
Blnk
Il7r
Rag1
Vpreb3
Dntt
Btla
Rag2
Igh-6
Tcrg-V4
Lef1
Igj
Tcrg-V2 / Tcrg-V3
Tcf7
Hbb-b1 /// Hbb-b2
Igf1
Hmox1
Ear1 / 12 /2/ 3
Axl
Spic
Epx
Hba-a1 /// Hba-a2
C1qc
Mrc1
C1qb
C1qa
Vcam1

Description
pre-B lymphocyte gene 1
immunoglobulin lambda-like polypeptide 1
early B-cell factor 1
B-cell linker
interleukin 7 receptor
recombination activating gene 1
pre-B lymphocyte gene 3
deoxynucleotidyltransferase, terminal
B and T lymphocyte associated
recombination activating gene 2
immunoglobulin heavy chain 6
T-cell receptor gamma, variable 4
lymphoid enhancer binding factor 1
immunoglobulin joining chain
T-cell receptor gamma, variable 2 / variable 3
transcription factor 7, T-cell specific
hemoglobin, beta adult major chain / minor chain
insulin-like growth factor 1
heme oxygenase (decycling) 1
eosinophil-associated, ribonuclease A family,
member 1 / 12 / 2 / 3
AXL receptor tyrosine kinase
Spi-C transcription factor (Spi-1/PU.1 related)
eosinophil peroxidase
hemoglobin alpha, adult chain 1 / chain 2
complement component 1, q C chain
mannose receptor, C type 1
complement component 1, q beta polypeptide
complement component 1, q alpha polypeptide
vascular cell adhesion molecule 1

Fold Change
-13.74
-11.71
-11.22
-8.47
-7.65
-7.63
-5.62
-5.18
-3.34
-3.22
-3.09
-2.74
-2.71
-2.65
-2.39
-2.23
3.33
3.55
4.73
4.89
5.00
5.21
5.34
6.21
10.63
16.06
16.78
20.52
28.75

Individual Fold changes of genes differentially expressed in GFP + LSKs compared to
GFP - LSKs (FDR<0.05 using LPE T-test) of GATA2-ERT transgenic mice.
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Figure 3-18. Schematic of the mutant GATA2-ERT retroviral vectors.
(A) Schematic of the GATA2-ERT retroviral vectors carrying the C352P and
C370P point mutations. (B) Amino acid sequences of the C-terminal Zinc Finger with the
locations of the point mutations. The four cysteine residues co-ordinating the zinc ion of
the 2nd finger are marked in green.
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(Figure 3-19A). Both the mutants also leaked into the nucleus of transduced BM cells
similar to the wildtype GATA2-ERT (Figure 3-19B). However the C352P and C370P
mutants showed a loss of DNA binding activity to the consensus WGATAR motif in gel
shift assay compared to wildtype GATA2-ERT (Figure 3-20). We then tested the
biological effects of the loss of DNA binding of the C352P and C370P mutations. Lack
of DNA binding activity abolished the growth advantage of GATA2-ERT transduced BM
cells over mock cells in liquid culture. GATA2-ERT wild type, two mutants and control
GFP transduced BM cells were diluted with mock cells to achieve around 25% GFP+
cells. After 12 days in culture the percentage of GFP+ ve cells in the GATA2-ERT group
was 91%±6 compared to C352P and C370P mutants and GFP group which remained at
32%±7.5 , 40%±10 and 38%±14 (Figure 3-21A).
The C352P and C370P mutations also abolished the self-renewal capacity of
GATA2-ERT in serial CFU-C assays. The cells harvested from the primary colonies of
GATA2-ERT wild type group formed at least 7-fold higher secondary colonies than the 2
mutants and the control GFP groups (Figure 3-21B). Finally to test if DNA binding is
required for myeloid expansion and lymphoid block in vivo, transplant experiments were
performed as described above with the C352P mutant. At 12 weeks post-transplant
undiluted GATA2-ERT recipients showed low GFP marking in B220+ cells (25%) and
CD3+ cells (50%) with high marking in Gr1+Mac1+ cells (94% ) when compared to the
control undiluted GFP recipients showing uniform GFP marking in all three subsets
(B220+ 76%, CD3+ 73%, Gr1+Mac1+ 84%) (Figure 3-22A). The GATA2-ERT
recipients also showed higher GFP MFI in the myeloid cells compared to the lymphoid
cells indicating that there exists a dose dependent lymphoid block and only low
expressing B and T cells escape the block (Figure 3-22B and C). The undiluted C352P
mutant group show higher GFP marking in B220+ cells (50% ) and CD3+ cells (46%)
similar to the Gr1+ Mac1+ cells (75%) resembling the GFP groups (Figure 3-22A). The
C352P recipients also show similar GFP MFI between the myeloid and lymphoid subsets
which show that the dose dependent lymphoid block requires DNA binding activity
(Figure 3-22B and C). However since the GFP percentage and MFI of CD3 + ve cells is
similar between the GATA2-ERT and C352P groups it is still possible that the T-cell
block is mediated by protein-protein interactions. Upon four-fold dilution with mock cells
only the GATA2-ERT wild type maintained high GFP% in Gr1+ Mac1+ cells (62%)
compared to the C352P (19%) and control GFP (34%) groups. This demonstrates that the
DNA binding activity of the GATA2-ERT is also required for myeloid expansion in vivo.
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Figure 3-19. Expression and subcellular localization of GATA2-ERT mutants in
primary BM cells.
Lin - BM cells were transduced with the wild-type and mutant GATA2-ERT vectors and
control GFP vector at similar MOI. (A) At the 3 days post-transduction proteins were
isolated and western blotted for GATA2-ERT (α ER alpha) and GAPDH. All the groups
had similar GFP percentages (60% to 70%). (B) Immunostaining was also performed at
the same time point post-transduction. Cells were attached to retronectin coated
coverslips for 40 minutes before fix and stain. Red represents GATA2-ERT (1°-αER
alpha, 2°- α-rabbit Alexa Flour 555), blue represents DAPI and Green represents GFP.
Imaging was performed using Zeiss LSM 510 Meta point scanning confocal microscope
with a Plan Apochromat 63X/1.4 Oil objective and zoom scan of 3.0.
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Figure 3-20. C352P and C370P are DNA binding defective mutants of GATA2.
Electrophoretic Mobility Shift Assay (EMSA) of wild type and mutant GATA2 and
GATA2-ERT proteins. GATA2 and GATA2-ERT proteins were synthesized from
pCDNA3.1 expression vectors by in vitro transcription translation (TnT) and bound to
P32 labeled mouse alpha globin promoter oligonucleotide (containing a GATA binding
site) in the absence and presence of 500 fold unlabeled oligonucleotides (D). Position of
free probe and protein DNA complexes containing GATA2 and GATA2-ERT proteins
are indicated.
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Figure 3-21. DNA binding activity of GATA2-ERT is required for myeloid
expansion in vitro.
(A) FACS Analysis of GFP percentages of transduced lineage depleted BM cells at
different time points in liquid culture after transduction (n=3). Transduced cells were
diluted at day0 with mock transduced cells to start at a uniform GFP percentage (25% to
28%) in all samples. (B) Total CFU-Cs from primary and secondary colony plating of
transduced lineage depleted BM cells. Cells were plated at 1.25X103 per plate in the
primary plating followed by 2.5X104 per plate for secondary plating.
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Figure 3-22. DNA binding activity of GATA2-ERT is required for myeloid
expansion and lymphoid block in vivo.
(A) FACS analysis of GFP percentages in B220 + cells, CD3 + cells and Gr1 + Mac1 +ve
cells (myeloid) in peripheral blood of recipients 12 weeks post-transplant. Values are
represented as Mean ± S.D of 10 recipients in each group. (B) Comparison of GFP
expression between B220 + cells, CD3 + cells and Gr1+ Mac1+ cells (myeloid) in
representative GFP, GATA2-ERT and C352P transplant recipients at 16 weeks posttransplant. (C) GFP Mean Fluorescence Intensity (MFI) Ratios in myeloid cells against
B220 + and CD3 + cells in GFP, GATA2-ERT and C352P transplant recipients at 16
weeks post-transplant (n=10).
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CHAPTER 4.

DISCUSSION

GATA2 Dose and Lineage Commitment
In this study, using retroviral transduction of GATA2-ERT vector into BM stem
and progenitor cells followed by transplantation, we show that nuclear concentrations of
the transcription factor GATA2 differentially regulate the development of granulocytes,
T-lymphocytes and B-lymphocytes. High nuclear concentrations of GATA2 resulted in
granulocyte development whereas moderate and low concentrations resulted in Tlymphocyte and B-lymphocyte differentiation respectively. This conclusion was made
from the observation that in the peripheral blood of GATA2-ERT transplant recipients,
highest GFP expression (as measured by the MFI) was seen in the Gr1+ Mac1+
granulocytes, followed by a moderate GFP expression in the CD3+ T-lymphocytes and
lowest GFP expression in the B220+ B lymphocytes.
Since the retroviral vector is bi-cistronic in which GFP is linked to GATA2-ERT
by the ires, GFP and GATA2-ERT are co-expressed at the mRNA level. In the myeloid
GATA2-ERT cell lines, a correlation at the protein level was also confirmed. In the
knockdown experiments on the GATA2-ERT cell lines, high GFP expression in the
“Non-silencing group “was consistent with the high GATA2-ERT protein levels
compared to the “shGFP” group in which low GFP expression was consistent with low
GATA2-ERT protein levels.
Our findings have two possible explanations. In the first scenario, in a myelolymphoid progenitor different doses of GATA2 results in different cell fates (Figure
4-1A). Alternatively, the lymphoid and myeloid differentiation can be initiated at the
same dose of GATA2 but in order to complete the differentiation GATA2 needs to be
downregulated to different levels in the myeloid and lymphoid lineages (Figure 4-1B). I
favor the second explanation for the following reasons. Firstly, in the GATA2-ERT
transgenic mice there was no difference in the GFP expression between the CLP and
CMP and the lymphoid block occurs only after the CLP and ETP. The high GFP
expressing myeloid cells were also selected only after the GMP stage (data not shown).
Secondly, the endogenous GATA2 expression is very high in the multipotent progenitors
(LSK cells) and seems to decrease upon differentiation to both the CLP and CMP. Even
though endogenous GATA2 expression in the CLP is lower than the CMP; this low
expression is not maintained but is even further reduced upon differentiation to the
mature cells.
The hypothesis that GATA2 needs to be down-regulated to different levels for
multi-lineage differentiation also agrees with the previous report from our lab that
enforced expression of GATA2 at the “HSC dose” leads to a complete block in multilineage differentiation. In the previous study MSCV-GATA2iresGFP vector resulted in
GATA2 expression similar to that of the Lin- Sca1+ HSCs.95 Endogenous GATA2
expression is highest in the HSCs and since the vector maintained the HSC dose, these
HSCs did not differentiate. The current MSCVGATA2-ERTires GFP vector achieves the
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Figure 4-1. Models of GATA2 dose dependent lineage commitment.
(A) Different doses of GATA2 results in different cell fates in a myelo-lymphoid
progenitor (LMPP). (B) Both lymphoid and myeloid differentiation can be initiated at the
same dose of GATA2 but in order to complete the differentiation GATA2 need to be
downregulated to different levels in the myeloid and lymphoid lineages. CMP: Common
Myeloid Progenitor, ETP: Early Thymic Progenitor, CLP: Common Lymphoid
Progenitor, HSC: Hematopoietic Stem Cell.
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same transgene mRNA expression, but achieves a much lower GATA2 nuclear protein
levels due to the protein distribution between the nucleus and the cytoplasm. This
resulted in normal multi-lineage differentiation and led to the identification of GATA2
dose effects further downstream in different lineages.
In the erythroid lineage GATA2 down regulation is mediated by GATA1.
GATA1 is highly expressed in erythro-megakaryocytic lineages, whereas it is suppressed
in HSCs and progenitor cell fractions.130 During erythroid differentiation GATA1 binds
to regulatory elements in the GATA2 locus by displacing GATA2. This phenomenon
called “GATA switch” results in down regulation of GATA2.87 The factors involved in
GATA2 down regulation during myeloid and lymphoid differentiation still remain to be
identified.
Dose dependent activity of transcription factors has been previously reported in
normal hematopoiesis and leukemia.137 Best studied is the transcription factor PU.1.
When Pu.1-/- fetal liver hematopoietic progenitors were transduced with retroviral vector
carrying PU.1 –GFP, the rescued Pro B-cells and macrophages had high and low GFP
expression respectively.46 The authors showed that low PU.1 protein is associated with a
B lymphoid fate and a high PU.1 protein was associated with a macrophage fate.
Gradual decrease in GATA2 expression show that the HSC transcription program
does not terminate abruptly during differentiation but persists during many stages.
Myeloid lineage may be more permissive to the HSC program than the lymphoid lineage.
This can explain the lower GATA2 threshold in the lymphoid lineage compared to the
myeloid lineage.
GATA2 and HSC Quiescence
The HSCs remain highly quiescent compared to the progenitor cells which have
prodigious proliferative capacity. Detailed cell cycle analysis and BrDU labeling assays
revealed that most of the HSCs are non-dividing with only 1-3% in cycle and
approximately 90% in G0 phase.11,138,139 A quiescent HSC population that divides only 5
times during the lifespan of the mice was also demonstrated.140 Quiescence has been
postulated to prevent stem cell exhaustion and is thought to protect stem cells from
acquiring mutations leading to their malignant transformation to putative cancer stem
cells.
Several components of the cell cycle machinery like cyclin dependent kinase
inhibitors (p21, p27, p16 and p18), D type cyclins and their associated kinases (Cdk4 and
Cdk6) have been shown to be critical for HSC quiescence.141 However the transcriptional
control of these components of cell cycle machinery still remains to be elucidated. Our
data show that GATA2 inhibits cell cycle in BM cells in a dose-dependent manner. In the
GATA2-ERT cell lines we observe a higher nuclear concentration in the presence of
TAM and a lower nuclear concentration in the absence of TAM. This high GATA2
concentration resulted in a cell cycle arrest at G0/G1 phase. Similarly in CFU-C assays,
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in the presence of TAM there is no colony formation and in the absence of TAM there is
an increased self-renewal of CFU-C forming progenitors
Our data is consistent with the previous studies with GATA2-ER vectors. When
GATA2-ER was expressed in hematopoietic cell lines (FDCP Mix, BaF3 and 32D) and
primary murine BM cells and Sca+ Lin- progenitors it resulted in a ligand induced block
in proliferation and cell cycle arrest.106,142 The GATA2-ERT mediated quiescence in
BaF3 cells was shown to be reversible upon removal of Tamoxifen.96 High expression of
GATA2 is associated with quiescence in both human and mouse HSCs. Two fold higher
GATA2 expression was found in quiescent compared to cycling CD34+ CD38- human
cord blood HSCs.96 Higher GATA2 expression was found in the quiescent adult mouse
BM HSCs compared to the cycling fetal liver HSCs.143 GATA2 expression was
progressively down-regulated when the adult BM HSCs were induced to cycle after 5-FU
treatment and returned to normal when the quiescence was reset.143 All these data
strongly suggest that GATA2 could mediate HSC quiescence in a dose dependent
manner.
GATA2 Mediated Myeloid Expansion
Persistent GATA2 expression not only favors a granulocyte cell fate choice but it
also expands myeloid cells. GATA2-ERT expressing BM cells effectively out-compete
mock transduced cells under myeloid conditions in vitro. In competitive transplant
experiments, GATA2-ERT expressing cells also effectively out-compete mock
transduced cells in the myeloid compartment. Even after transplanting GATA2-ERT
expressing BM cells at 1:4 dilutions with mock cells, the recipients had an 82% GFP
marked Gr1+ Mac1+ granulocytes.
The myeloid expansion is due to GATA2-ERT mediated increased self-renewal of
the myeloid progenitors. In myeloid CFU-C assays, GATA2-ERT expressing myeloid
progenitors formed larger size colonies which can further form colonies upon serial
replating. This increased ability to form secondary colonies is a sign of increased selfrenewal. The myeloid progenitor that acquired increased self-renewal is probably the
Granulocyte Monocyte Progenitor (GMP).This agrees with the observation that myeloid
expansion in the GATA2-ERT transgenic mice starts at the GMP stage. This is also
consistent with the previous reports that GATA2+/- BM have reduced cellularity in the
GMP compartment and formed reduced GM colonies in CFU-C assays.144
It is also possible that the increased self-renewal of myeloid progenitors by
retroviral transduction of MSCV GATA2-ERTires GFP vector can be due to “insertional
mutagenesis”. Insertion of a gamma retrovirus neighboring an oncogene can be followed
by its aberrant expression due to the enhancer effects of the viral LTR elements.
Alternatively the insertion of the gamma retrovirus can also disrupt and inactivate a
tumor suppressor gene. Both these effects can cause myeloid expansion independent of
GATA2-ERT. However loss of GATA2-ERT in the GATA2-ERT transduced cell lines
leads to loss of the self-renewing Gr1 negative progenitor population. This is followed by
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complete differentiation into mature Gr1 positive cells and loss of proliferation in these
cell lines. These data suggests that GATA2-ERT expression is essential for the continued
proliferation and self-renewal of the myeloid progenitors and also that GATA2-ERT
plays a direct role in these effects. It still remains possible that GATA2-ERT could exert
these effects in co-operation with an un-identified gene which was insertionaly
mutagenized. However GATA2-ERT vector immortalizes BM cells at a very high
frequency than the GFP vector in vitro and also expands myeloid cells consistently in all
transplant recipients. It is unlikely that the GATA2-ERT vector integrates next to the
same co-operating gene in multiple experiments further arguing that these effects are
mediated by GATA2-ERT alone.
Requirement of high expression of Nmyc and HoxA9 in the GATA2-ERT cell
lines suggest that Nmyc and hoxA9 could be potential GATA2 targets in myeloid
progenitors. Enforced expression of Nmyc by itself increased the proliferation and selfrenewal of myeloid progenitors.145 These effects were thought to be mediated by downregulation of TGF-β signaling, upregulation of Smad7 and JNK signaling pathways.145
However these pathways were not affected by GATA2-ERT mediated Nmyc
overexpression suggesting that the mechanism of Nmyc action could be different in the
context of GATA2. Overexpression of HoxA9 is common in human mixed lineage
leukemia (MLL) and is required for MLL fusion protein mediated transformation in a
murine bone marrow transduction/transplantation model.146,147 Overexpression of HoxA9
in the BM cells expands myeloid cells with a block in lymphoid development at the PreB cell stage.148 Overexpression of HoxA9 also immortalized BM cells into GM-CSF
dependent pro-myelocyte cell lines.149 Since the GATA2-ERT induced myeloid
expansion is dependent on its DNA binding activity, GATA2-ERT could possibly bind to
both Nmyc and HoxA9 locus resulting in their up-regulation. However the absence of
GATA2-ERT chromatin occupancy in both the Nmyc and HoxA9 locus suggests that
both Nmyc and HoxA9 could both be secondary targets of GATA2. Alternatively
GATA2 could still bind to distant regulatory elements in the Nmyc and HoxA9 locus
which were not tested in the ChIP assay. Such distal binding sites could be identified by
performing ChIP-Seq analysis.
GATA2 Mediated Lymphoid Block
Gene expression analysis on various hematopoietic stem and progenitor
populations has shown a low promiscuous expression of genes from different lineages
that the multipotent cell can potentially differentiate into.150-152 This process is called
“Lineage Priming”. For example both lymphoid and myeloid specific genes were
expressed in a Lympho-myeloid progenitor (LMPP) and both T-cell and B-cell lineage
genes were expressed in a CLP. This is thought to be a consequence of alterations in
chromatin structure which allows accessibility to various transcriptional regulators. This
could also be due to the simultaneous expression of TFs of the respective conflicting
lineages being expressed at low doses.
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Loss of lymphoid lineage priming in the MPPs has been associated with a block
in lymphoid differentiation in a few gene knockouts. Ikaros knockout mice show an
absence in B-cell development and T-cell defects. Ikaros had been shown to be essential
for priming of lymphoid genes throughout the lymphoid differentiation starting from the
HSC.153 One mechanism is thought to be chromatin remodeling because Ikaros interacts
with the Nucleosome remodeling complex (NuRD).154 Recently it has been shown that
Ikaros needs to interact with the GATA family of transcription factors and Cdk9 protein
for appropriate chromatin binding and activation of its target genes.155 Ikaros was shown
to interact with GATA2 in hematopoietic progenitors, GATA1 in erythroid cells and
GATA3 in lymphoid cells. One mechanism by the sustained GATA2 expression in the
MPPs and/or CLP can prevent Ikaros GATA3 binding thereby preventing Ikaros
mediated lymphoid priming. Other gene knockouts which can cause lymphoid priming
defects in the MPPs are Mef2c and E2A.156,157 Both Mef2ca and E2A are required for
lymphoid differentiation.
Gene expression analysis on GATA2-ERT expressing MPPs show a
downregulation of lymphoid specific signaling (IL7R), transcription factors
(Ebf1,Lef1,Tcf7) and effectors (Rag1,Rag2,Dntt,Btla,Vpreb1 ,Igh-6,Tcrg ). There was a
considerable overlap of genes downregulated in the Mef2c-/- MPPs and GATA2-ERT
expressing MPPs and that were E2A or EBF targets (Rag1, Dntt, Igh-6 and Tcf7).157 We
hypothesize that sustained expression of GATA2 could antagonize the activity of
transcription factors E2A, Mef2c and EBF to prevent lymphoid priming in the MPPs.
Since the block in B-cell differentiation mediated by GATA2-ERT is dependent on its
DNA binding activity, it is possible that GATA2 could bind to these lymphoid specific
genes loci and prevent their transcription. GATA2 could additionally prevent the binding
of other lymphoid specific TFs at these loci.
It is not clear whether the T-cell block is due to DNA binding activity of
GATA2.The C352P transplant recipients showed similar GFP marking in T-cells
compared to the wild type GATA2-ERT recipients. However the T-cell GFP marking
approximates the myeloid GFP marking in the C352P recipients than the wildtype
GATA2-ERT recipients. It is possible that titration of a T-cell lineage specific TF by
GATA2-ERT in the cytoplasm due to protein-protein interaction can lead to the Tlymphoid block. The lymphoid priming of such TFs will possibly be unaffected by
GATA2-ERT. Some of the lymphoid specific transcription factors like Ikaros, GATA3
and Ets1 were not differentially regulated in the MPP and could be potential candidates in
this context.

GATA2 Overexpression in Acute Myeloid Leukemia (AML)
GATA2 overexpression is frequently observed in Acute Myeloid Leukemia. In a
recent study with a large series of AML patients GATA2 was overexpressed in 37.4% of
cases (97/259) as measured by real-time RT-PCR.158 GATA2 overexpression was also
significantly associated with FLT3-ITD and NPM1 mutations and overexpression of
WT1 and Evi1.158 In another study with pediatric AML patients GATA2 was
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overexpressed in 65% of cases (155/237).159 During complete remission GATA2
expression returned to normal but remained high in patients with resistant disease.159
GATA2 overexpression also correlated with a poor prognosis in patients receiving
chemotherapy in both studies. GATA2 overexpression could possibly transform a normal
myeloid progenitor cell like CMP or GMP into a Leukemic Stem cell (LSC) by
conferring high proliferation and self-renewal capacity and also leading to additional
mutations. Alternatively GATA2 overexpression can be a part of gene expression
program inherited from a HSC which was transformed into a LSC by a different driver
mutation.
Expression of many leukemic gene fusions like MLL-ENL, MLL-AF9, MOZTIF2 and NUP98-HOXA9 can cause increased self-renewal of myeloid progenitors,
immortalization of primary BM cells in vitro, and leukemia formation upon
transplantation.160-164 In our study expression of GATA2-ERT immortalized primary BM
cells into IL-3 dependent myeloid cell lines. GATA2-ERT expression also increased the
self-renewal and proliferation of myeloid progenitors. However no leukemia was
observed upon transplantation. The GATA2-ERT transgenic mice even when crossed
with p16/p18 dko mice or p21/p27 dko did not show an increase in incidence of leukemia
generation. These data suggest that additional cooperating mutations that can block
differentiation may be required to transform GATA2-ERT expressing myeloid
progenitors into LSCs.
Targeting the GATA2 mediated transcriptional network in the LSCs could be a
potential strategy in AML treatment. In our studies knockdown of GATA2-ERT and its
targets hoxA9 and Nmyc, in the immortalized cell lines differentiated these cells and
stopped their proliferation. It will be interesting to test if patient derived AML cell lines
are dependent on GATA2 for their proliferation. Such a strategy was employed in Ras
oncogene driven Non-small cell lung cancers (NSCLC) which required GATA2 for their
survival.165 GATA2 was found to transcriptionally regulate NFκB, proteasome and Rho
signaling pathways and targeting these pathways reduced tumor development in lung.165
In our gene expression studies on GATA2-ERT cell lines we did not identify these
pathways suggesting that mechanisms could be different in hematopoietic neoplasms.
GATA2 Mutations in Familial AML/MDS Syndromes
Mutations in GATA2 have been identified recently in rare familial disorders like
DCML, MonoMAC syndrome and Emberger syndrome all of which have a
predisposition to MDS and AML.119-121 DCML and MonoMAC syndromes are closely
related syndromes characterized by monocytopenias, B-cell and NK cell lymphopenias
associated with mycobacterial, fungal and viral infections and predisposition to
MDS/AML.166,167 Emberger syndrome is characterized with severe lymphedema in
addition to predisposition to MDS and AML.GATA2 mutations were also associated with
familial MDS/AML syndromes without any other hematopoietic and vascular defects.118
All these syndromes show an autosomal dominant inheritance with incomplete
penetrance.
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Mutations of GATA2 found in these syndromes are highly heterogeneous ranging
from deletions, frame-shift mutations leading to premature termination and point
mutations. Since one wild-type allele was always present, some of the mutations
(deletions and frame-shift) were thought to result in GATA2 haplo-insufficiency and lead
to the disease. However in the case of point mutations the question remained whether the
mutation could be dominant negative rather than a loss of function. Almost all of the
point mutations were found in the 2nd zinc finger domain which is important for DNA
binding of GATA2 and protein-protein interactions. The Thr354Met and Thr355Del
mutations both showed loss of DNA binding activity in gel shift and luciferase assays.118
Surprisingly Thr354Met showed some dominant negative effects in ATRA induced
differentiation of HL-60 cells.118
In our study we artificially designed two GATA2 DNA binding mutants (C352P
and C370P) with mutations in the 2nd zinc finger. Both these mutants abolished the
myeloid expansion and lymphoid block mediated by sustained GATA2 expression. These
results favor the hypothesis that the 2nd zinc finger missense mutations found in patients
are probably loss of function mutations and the disease is caused by GATA2 haploinsufficiency. GATA2+/- mice are viable but have “smaller HSC pool size” due to defects
in HSC specification.91 Under stress conditions like infections, due to enormous
requirement of mature cells, there can be a HSC exhaustion leading to MDS and finally
AML.
In our study the sustained GATA2 expression leads to B-cell specific block. This
block is not associated with monocytopenia but rather an expansion of Gr-1+, mac1+
cells. In contrast in the DCML and MonoMAC syndromes the B-cell deficiency is
associated with deficiency of CD14+ monocytes and NK cells. This suggest that the
mechanism of B-cell block in DCML and MonoMAC is probably not sustained GATA2
expression in CLP but a GATA2 haplo-insufficient HSC under stress generating less
mature cells. BM analysis of MonoMAC patients also showed absence of multi-lymphoid
progenitors and GMPs confirming this hypothesis.166
Technical Considerations in Using the GATA2-ERT System
In the absence of TAM, GATA2-ERT protein is localized in both the nuclear and
cytoplasmic fractions of BM cells. The leaky nature of the GATA2-ERT protein calls for
two explanations for the observed phenotype. DNA binding and transcriptional regulation
by the GATA2-ERT leaking into the nucleus or the retention of other factors by the
cytoplasmic GATA2-ERT. To distinguish between these two mechanisms we used the
DNA binding GATA2-ERT mutants, C352P and C370P. These two mutations were made
in the cysteine residues of 2nd zinc finger domain of GATA2. The C352P was used
previously by other groups to study functions of both GATA1 and GATA2.74,135,136 The
myeloid expansion in vitro (CFU-C replating assay and proliferation assay) and in vivo
(competitive transplants) were completely dependent on DNA binding of the leaky
GATA2-ERT. The B lymphoid block was also dependent on DNA binding activity of
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GATA2-ERT. On the other hand it is unclear whether T-cell block is due to DNA
binding activity or protein-protein interactions.
The GATA2-ERT system we used contains a human GATA2 cDNA that was
overexpressed in mouse hematopoietic tissues. Both human and mouse GATA2 are 480
amino acids long with 98% similarity in amino acid composition. None of the amino acid
changes are located it the critical zinc finger domains suggesting that both the mouse and
human GATA2 probably behaves similarly in functional assays. In the GATA2-ERT
transgenic mice, the developing immune system should recognize the human GATA2
protein as self-protein and do not develop antibodies against it. Similarly the transplant
recipients should also tolerate human GATA2 expressing BM cells since they received
immune ablation before transplant.
Even though the GATA2-ERT system is advantageous because it achieved low
doses of GATA2, the system has some drawbacks. It is possible that the GATA2-ERT
fusion protein can have a different DNA binding and transactivation properties than the
wild-type GATA2. GATA2-ERT may not fit easily into mult-protein complexes due to
the presence of the extra ERT domain. However in functional assays, GATA2-ERT in
presence of Tamoxifen completely blocked CFU-C colony formation an effect similar to
the wild-type GATA2. This shows that minor differences in protein structure are
tolerated in vivo. It will also be interesting to test if the effects of MSCV-GATA2-ERT
vector can be replicated when wild-type GATA2 is driven from a weak promoter or an
inducible promoter (Tet-Off systems).
Future Directions
Using the GATA2-ERT system we presented evidence that GATA2
overexpression confers increased self-renewal of myeloid progenitors and that lower dose
of GATA2 is critical for this phenotype. To overcome the drawbacks of the ERT fusion
system we need to confirm if this effect can be replicated when wild-type GATA2 is
driven from a weak promoter or a tetracycline inducible promoter. Identification of
GATA2 targets that mediate the self-renewal effect is important for development of AML
therapy and also HSC expansion protocols. The mechanism by which GATA2 regulates
Nmyc and HoxA9 potential targets in our study can be addressed by ChIP-Seq
experiments on the GATA2-ERT cell lines.
Our studies show that GATA2 overexpression by itself is insufficient to initiate
leukemia in transplant and transgenic animals. It will be interesting to test if Flt3-ITD or
NPM1 mutations can co-operate with GATA2 overexpression to initiate leukemia. It is
unclear how GATA2 is overexpressed in AML. Possible mechanisms could be
translocations near GATA2 locus, epigenetic modifications or activation by an upstream
regulator of GATA2.
Down regulation of GATA2 is a critical step for the multi-lineage differentiation
of HSCs. Our data show that dysregulation of this process can lead to lymphoid block
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and myeloid expansion. Identification of factors that down regulate GATA2 in various
lineages is crucial for our understanding of hematopoiesis. In the erythroid lineage the
transcription factor GATA1 has been shown to down regulate GATA2 by transcriptional
repression.98 It will be important to identify the factors that down regulate GATA2 in
myeloid and lymphoid lineages.
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